



**UNIVERSITI PUTRA MALAYSIA**

**3,19-DIACETYL-14-DEOXY-11,12- DIDEHYDROANDROGRAPHOLIDE  
(SRS27) ANTAGONISES INFLAMMATORY RESPONSE AND OXIDATIVE  
STRESS IN *IN VITRO* AND *IN VIVO* ASTHMA MODELS**

**LIM CHEE WOEI**

**FPSK(p) 2014 10**



**3,19-DIACETYL-14-DEOXY-11,12-  
DIDEHYDROANDROGRAPHOLIDE (SRS27)  
ANTAGONISES INFLAMMATORY RESPONSE  
AND OXIDATIVE STRESS IN *IN VITRO* AND *IN  
VIVO* ASTHMA MODELS**

**LIM CHEE WOEI**

**DOCTOR OF PHILOSOPHY  
UNIVERSITI PUTRA MALAYSIA**

**2014**



**UPM**  
UNIVERSITI PUTRA MALAYSIA  
BERILMU BERRAKTI

**3,19-DIACETYL-14-DEOXY-11,12-  
DIDEHYDROANDROGRAPHOLIDE (SRS27) ANTAGONISES  
INFLAMMATORY RESPONSE AND OXIDATIVE STRESS IN *IN*  
*VITRO* AND *IN VIVO* ASTHMA MODELS**

By

**LIM CHEE WOEI**

**Thesis Submitted to the School of Graduate Studies,  
Universiti Putra Malaysia, in Fulfilment of the  
Requirements for the Degree of Doctor of Philosophy**

**June 2014**

## COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

**3,19-DIACETYL-14-DEOXY-11,12-DIDEHYDROANDROGRAPHOLIDE (SRS27) ANTAGONISES INFLAMMATORY RESPONSE AND OXIDATIVE STRESS IN *IN VITRO* AND *IN VIVO* ASTHMA MODELS**

By

**LIM CHEE WOEI**

**June 2014**

**Chairman : Johnson Stanlas, PhD**

**Faculty : Medicine and Health Sciences**

Corticosteroids and non-steroidal anti-inflammatories are the most effective treatments for a variety of inflammatory conditions such as asthma. Steroids act by blocking transcription factors, such as nuclear factor (NF)- $\kappa$ B and activator protein (AP)-1 to down-regulate a vast array of pro-inflammatory genes, whereas NSAIDs specifically target cyclo-oxygenase (COX) activity to reduce prostaglandin production. However, the use of both types of drugs is associated with unwanted side effects, and a significant proportion of patients are steroid resistant. Thus, there is an urgent need to develop novel anti-inflammatory drugs to replace or complement present day therapy.

The bioactive compounds from the famous Asian herb *Andrographis paniculata* (known locally in Malaysia as Hempedu Bumi) have been studied for almost a century. The focus has been placed on the identification of antiinflammatory and anticancer agents. The herb contains two main diterpenoid constituents named andrographolide (AGP) and 14-deoxy-11,12-didehydroandrographolide (DDAG). AGP and DDAG were found to exhibit anti-asthma effects by inhibiting inflammatory responses in an allergic mouse asthma model. As such, both of them could act as novel replacement for current anti-inflammatory drugs. However, due to inadequacies of both compounds in terms of drug-like properties, DDAG analogues were semisynthesised to tackle these shortcomings.

Among the analogues, 3,19-diacetyl-14-deoxy-11,12-didehydroandrographolide (SRS27) was proven to inhibit cysteinyl leukotriene (CysLT) and nitric oxide (NO) synthesis in mouse macrophages, like AGP. However, DDAG on the other hand, failed to exhibit such activity. SRS27 was less toxic compared with AGP, which suggests that a simple chemical modification of DDAG produces a compound with CysLT and NO inhibitory activity similar to AGP but maintained the toxicity profile similar to DDAG. It is interesting to note that other analogues such as SRS28, SRS49, SRS76 and SRS83 with chemical modifications on the same carbon numbers

3 and 19 of DDAG were unable to show inhibition of CysLT and NO synthesis.

Consequently, the potential anti-inflammatory effect of SRS27 was investigated in ovalbumin (OVA)-induced mouse asthma model. The compound was administered in a prophylactic manner and showed a substantial decrease in asthma parameters. SRS27 at 3 mg/kg twice daily for three days consecutively significantly reduced OVA-induced total cell such as macrophages, eosinophils, lymphocytes and neutrophils, as well as inflammatory cytokines such as IL-4, IL-5, IL-13 and eotaxin in bronchoalveolar lavage (BAL) fluid. The compound also suppressed serum IgE production. In addition, SRS27 suppressed mucus hyper-secretion and expression of inflammatory mediators such as TNF- $\alpha$ , MCP-1, Muc5ac, RANTES, IL-33 and iNOS. Mechanistically, the compound inhibited lung NF- $\kappa$ B p65 nuclear translocation. In line with this observation, p65 NF- $\kappa$ B nuclear translocation was also found to be inhibited by the compound in A549 lung cancer cell line. Notably, this inhibition was not a result of cell toxicity as peripheral blood count in normal BALB/C mice treated with 3 mg/kg of SRS27 was not affected. The acute toxicity in mice further supported this idea, which indicated SRS27 is indeed a safe compound, just like DDAG. A pharmacokinetic study in Balb/C mice at 3 mg/kg single dose revealed SRS27 that had a relatively short half-life but was able to achieve a concentration range of 13- 19  $\mu$ M concentration that could be related to *in vitro* anti-asthma activities. SRS27 is the first known DDAG derivative tested positive in a mouse asthma model and as such this compound could serve as a prototype and template for future improvement as a potential prophylactic agent to control asthma.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**3,19-DIACETYL-14-DEOXY-11,12-DIDEHIDROANDROGRAPHOLIDE (SRS27) MENGHALANG RESPON INFLAMASI DAN TEKAMAN OKSIDASI DI DALAM MODEL ASMA *IN VITRO* DAN *IN VIVO***

Oleh

**LIM CHEE WOEI**

**Jun 2014**

**Pengerusi : Johnson Stanslas, PhD**

**Fakulti : Perubatan dan Sains Kesihatan**

Kortikosteroid dan drug anti-inflamasi non steroid (DAINS) merupakan rawatan yang paling berkesan untuk pelbagai keadaan radang seperti asma. Steroid bertindak dengan menyekat faktor transkripsi, seperti factor nuklear (NF)  $\kappa$ B dan pengaktif protein (AP) -1 untuk merencat pelbagai gen prokeradangan, manakala DAINS bertindak ke atas aktiviti siklooksigenase (COX) dengan mengurangkan sintesis prostaglandin. Walaubagaimanapun, penggunaan kedua-dua jenis ubat tersebut memberi kesan sampingan yang tidak diingini, dan sebahagian besar daripada pesakit mengalami kerintangan terhadap steroid. Oleh sebab itu, keperluan untuk membangunkan ubat anti-inflamasi yang baharu untuk menggantikan atau sebagai pelengkap bagi terapi yang sedia ada adalah amat kritikal.

Sebatian bioaktif daripada salah herba terkenal di Asia, iaitu *Andrographis paniculata* (Hempedu Bumi) telah dikaji lebih daripada satu abad dengan tumpuan diberikan untuk mengenalpasti ejen anti-inflamasi dan antikanser. Herba ini mengandungi dua komponen utama diterpenoid iaitu andrographolide (AGP) dan 14 - deoxy- 11 ,12- didehidroandrographolide (DDAG). AGP dan DDAG didapati menunjukkan kesan anti asma apabila tindakbalas inflamasi dalam model alahan asma mencit berkurangan selepas diberi diterpenoid tersebut. Oleh itu kedua-dua komponen tersebut dilihat berpotensi menjadi penggantinya ubat anti-inflamasi semasa yang baharu. Walaubagaimanapun, disebabkan sebatian ini mempunyai ciri-ciri ubat yang tidak sesuai, analog DDAG dihasilkan untuk menangani kelemahan ini dan seterusnya kajian dilakukan untuk menjelaskan hubungan struktur - aktiviti.

Antara analog yang dikaji, 3,19-diacetyl-14-deoxy-11,12-didehidroandrographolide (SRS27) telah dibuktikan dapat merencat sintesis cysteinyl leukotriene (CysLT) dan nitrikoksida (NO) dalam makrofaj mencit, seperti AGP. Namun, DDAG didapati gagal untuk mempamerkan aktiviti sedemikian. SRS27 yang didapati kurang toksik berbanding dengan AGP, menunjukkan pengubahsuaian kimia yang mudah ke atas DDAG menghasilkan sebatian yang mengandungi aktiviti terhadap CysLT dan NO



seperti AGP dan mengekalkan profil ketoksikan seperti DDAG. Menariknya, analog lain seperti SRS28, SRS49, SRS76 dan SRS83 dengan pengubahsuaian kimia pada nombor karbon yang sama iaitu 3 dan 19 dalam DDAG didapati tidak menunjukkan aktiviti perencatan sintesis CysLT dan NO.

Selanjutnya, potensi kesan anti-inflamasi oleh SRS27 dikaji dalam model asma mencit diaruh dengan ovalbumin (OVA). SRS27 yang diberikan secara profilaktik menunjukkan penurunan ketara parameter asma. Sebatian ini yang diberikan secara intraperitonium pada dos 3 mg/kg sebanyak 2 kali sehari selama 3 hari berturut-turut telah mengurangkan jumlah sel yang diaruh oleh OVA seperti makrofaj, eosinofil, limfosit, dan neutrofil, serta sitokin inflamasi seperti IL-4, IL-5, IL-13 dan eotaxin dalam cecair bronchoalveolar (BAL lavage). Sebatian ini juga merencatkan penghasilan IgE. Disamping itu, ia juga dapat merencat rembesan lendir dan ekspresi pengantara inflamasi seperti TNF- $\alpha$ , PKM -1, Muc5ac, RANTES, IL-33 dan iNOS. Daripada sudut mekanisme, sebatian tersebut menghalang translokasi nukleus NF- $\kappa$ B p65 di dalam paru-paru. Selaras dengan pemerhatian ini, p65 NF- $\kappa$ B nuclear translokasi juga didapati direncatkan oleh sebatian tersebut di dalam sel kanser paru-paru (A549). Perencatan ini bukan terhasil akibat daripada ketoksikan sel dimana kiraan darah periferi dalam mencit BALB/C normal yang dirawat dengan 3 mg/kg SRS27 adalah tidak terjejas. Hasil kajian ketoksikan akut menggunakan model mencit telah menyokong idea ini dengan membuktikan SRS27 sebagai satu sebatian yang selamat seperti DDAG. Kajian farmakokinetik pula menunjukkan bahawa dos tunggal 3 mg/kg SRS27 mempunyai jangka separuh hayat yang agak singkat (4.8 min) tetapi mampu mencapai julat kepekatan maksima darah sebanyak 13 - 19  $\mu$ M yang boleh dikaitkan dengan aktiviti anti-asma *in vitro*. SRS27 merupakan analog DDAG yang pertama diuji positif dalam model asma mencit dimana ia berpotensi dijadikan sebagai sebatian prototaip dan templat untuk penambahbaikan sebagai sebatian profilaktik yang berpotensi untuk mengawal asma pada masa hadapan.



## ACKNOWLEDGEMENTS

First and foremost, I would like to take this opportunity to dedicate and express my sincere gratitude to my project supervisor, Prof. Dr. Johnson Stanslas for his constant and valuable guidance, encouragement, advice and remarkable understanding and knowledge throughout the course of my study.

In addition, my sincere appreciation goes to Assoc. Prof. Dr. Fred Wong Wai-Shiu and Prof. Dr. Shiran Md Sidek for their advices during the course of this project. I would like to specially thank Assoc. Prof. Dr. Fred Wong Wai-Shiu for his kind and generous hospitality during my one and half years of attachment in his lab. I would like to extend my appreciation to my fellow labmates from NUS, Fera Goh Yiqian, Alan Koh Hock Meng, Guan Shou Ping, Cherng Chang, Chan Tze Khee and David Chan for their ideas, help, troubleshooting and companionship during my attachment. Special thanks to my fellow friends, Kong Li Ren, Fhu Chee Wai, Robin Lim and Woo Chern Chiu for their hospitality and advices in ensuring my attachment ended with fruitful outcomes.

My heartfelt thanks and gratitude goes to all members of CRDD, especially Dr. Sreenivasa Rao Sagineedu for the synthesis work of andrographolide analogues; Ben Wong for his assistance and valuable advice; Dr. Rafid Salim Jabir for helping me with the statistical analysis. Special thanks to Velan Suppaiah, Wong Mei Szin, Ethel Jeyaraj, Noorlela Ramli, Michelle Wong, Cik Ruhaidah Ramli. I thank you for your assistance and contributions in different ways throughout my journey of completion of this project.

I am also grateful and honoured to have been awarded with a tutor contract by Universiti Putra Malaysia and KPT scholarship by Malaysia Ministry of Higher Education.

Lastly, my true admiration and heartiest appreciation goes out to my wife, Elaine Goh Hui Ling; father, Lim Mun Teck; mother, Yeow Lay Yoong; my brother, Lim Jun Hoh; my late grandmother, Tan Boon Lan; and those who are special to me, for their endless supports and concerns as well as their unrelenting love and understanding throughout the years of my study. I am forever indebted to my wife and family, for their presence, it would have been impossible for me to have this project completed. Therefore, this thesis is dedicated to them.



I certify that a Thesis Examination Committee has met on 2 June 2014 to conduct the final examination of Lim Chee Woei on his thesis entitled “3,19-Diacetyl-14-Deoxy-11,12-Didehydroandrographolide (SRS27) Antagonises Inflammatory Response and Oxidative Stress in *In Vitro* and *In Vivo* Asthma Models” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

**Lye Munn Sann, PhD**

Professor Dato'  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Fauziah Othman, PhD**

Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Brian P Kirby, PhD**

Lecturer  
RCSI Medical  
Perdana University – Royal College of Surgeons in Ireland  
Malaysia  
(External Examiner)

**Gautam Sethi, PhD**

Assistant Professor  
National University of Singapore  
Singapore  
(External Examiner)

---

**NORITAH OMAR, PhD**

Associate Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 18 August 2014

This was thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Johnson Stanslas, PhD**

Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Shiran bin Mohd Sidik, MBBS, M Path, AM**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Fred Wong Wai-Shiu, PhD**

Associate Professor  
Yong Loo Lin School of Medicine  
National University of Singapore  
Singapore  
(Member)

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/ fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name and Matric No.: **LIM CHEE WOEI (GS22869)**

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_  
Name of  
Chairman of  
Supervisory  
Committee: Johnson Stanslas

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: Shiran bin Mohd Sidik

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: Fred Wong Wai-Shiu

Signature: \_\_\_\_\_  
Name of  
Member of  
Supervisory  
Committee: \_\_\_\_\_

## TABLE OF CONTENTS

	Page
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xv
<b>LIST OF FIGURES</b>	xvi
<b>LIST OF ABBREVIATIONS</b>	xxi
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	
1.1 Background of the Study	1
1.2 Problem Statements	1
1.3 Significance of the Study	2
1.4 Hypothesis	2
1.5 Objectives of the Study	2
1.5.1 Main Objective	2
1.5.2 Specific Objectives	2
<b>2 LITERATURE REVIEW</b>	
2.1 Asthma	3
2.2 Prevalence of Asthma	3
2.3 Pathophysiology of Allergic Asthma	6
2.3.1 Th2 Inflammatory Pathway	6
2.3.2 Th1 Cells	8
2.3.3 Eosinophilic Airway Inflammation	8
2.3.4 Airway Hyper-responsiveness	9
2.3.5 Airway Remodelling	9
2.3.6 Airway Mucus Hyper-secretion	10
2.3.7 Elevated Serum Level IgE	11
2.3.8 Nuclear Factor-KappaB in Asthma	11
2.3.9 Cysteinyl Leukotriene in Allergic Asthma	13
2.3.10 Nitric Oxide in Asthma	14
2.4 Current Treatment for Allergic Asthma	16
2.4.1 $\beta$ 2-adrenoceptor agonists	16
2.4.2 Anticholinergic Agents	17
2.4.3 Phosphodiesterase Inhibitors	17
2.4.4 Corticosteroids	18
2.4.5 Mast Cell Stabilizing Drugs	19
2.4.6 Drugs Targeting IgE	19
2.4.7 Allergen Immunotherapy	20
2.4.8 Cytokine-based Immunotherapy	20
2.4.9 Drugs Targeting Leukotriene	21
2.5 Pharmacological Activities of New Compounds from <i>Andrographis paniculata</i>	22
2.5.1 Andrographolide and 14-deoxy-11,12-didehydroandrographolide	23
2.5.2 Andrographolide Analogues	26

<b>3</b>	<b><i>IN VITRO</i> ANTI-NITRIC OXIDE AND ANTI-CYSTEINYL LEUKOTRIENE SYNTHESIS ACTIVITIES OF ANDROGRAPHOLIDE AND ITS DERIVATIVES</b>	
3.1	Introduction	28
3.2	Materials	30
3.2.1	Compounds Isolation and Synthesis	30
3.2.2	Cell Lines	30
3.2.3	Reagents and Chemicals	30
3.2.4	Tissue Culture Materials	30
3.2.5	Animals	31
3.2.6	Instrumentations	31
3.3	Methods	31
3.3.1	Cell Culture	31
3.3.2	Plating	32
3.3.3	Cryogenic Preservation and Recovery	32
3.3.4	Compounds Dilution and Preparation	32
3.3.5	In vitro cytotoxicity assay (MTT assay)	33
3.3.6	Griess Assay	33
3.3.7	Induction and Harvesting of Mouse Peritoneal Macrophages	33
3.3.8	Plating of Mouse Peritoneal Macrophages and Treatment	34
3.3.9	Cysteinyl Leukotriene Measurement	34
3.3.10	Structure-Property Analysis of DDAG Derivatives	35
3.3.11	Statistical Analysis	35
3.4	Results	35
3.4.1	Cysteinyl Leukotriene	35
3.4.2	Nitric Oxide	38
3.4.3	Toxicity profile of AGP, DDAG and SRS27	41
3.4.4	Structure-Property Analysis of DDAG Derivatives	44
3.5	Discussion	46
3.6	Conclusion	49
<b>4</b>	<b><i>IN VITRO</i> INHIBITORY ACTIVITY OF SRS27 AGAINST NF-<math>\kappa</math>B SIGNALLING PATHWAY</b>	
4.1	Introduction	50
4.2	Materials	51
4.2.1	Compounds Isolation and Synthesis	51
4.2.2	Cell Lines	51
4.2.3	Reagents and Chemicals	51
4.2.4	Tissue Culture Materials	51
4.2.5	Instrumentations	51
4.3	Methods	52
4.3.1	Cell Culture	52
4.3.2	Drug Treatment and TNF- $\alpha$ stimulation	52
4.3.3	Biological Response Study	52
4.3.3.1	RT-PCR	52
4.3.3.2	Polymerase chain reaction	53
4.3.3.3	Gel electrophoresis	53



4.3.4 Protein Study	53
4.3.4.1 Total protein extraction	53
4.3.4.2 Nuclear protein extraction	54
4.3.4.3 Western Blot	54
4.3.4.4 NF- $\kappa$ B Transcription Factor Assay (Trans-AM Assay)	55
4.4. Results	
4.4.1 Effects of andrographolide analogues on the NF- $\kappa$ B-activated biological response	55
4.4.2 Effects of andrographolide analogues on DNA-binding activity	57
4.4.3 Effects of andrographolide analogues on TNF- $\alpha$ -induced NF- $\kappa$ B activation	58
4.5 Discussion	60
4.6 Conclusion	62
<b>5 MOUSE ASTHMA MODEL</b>	
5.1 Introduction	64
5.2 Materials	66
5.2.1 Compounds Isolation and Synthesis	66
5.2.2 Animals	66
5.2.3 Chemicals and Reagents	66
5.2.4 Laboratories Wares and Consumables	67
5.2.5 Instrumentations	67
5.3 Methods	67
5.3.1 <i>In vivo</i> preparation of SRS27 solution	67
5.3.2 Mouse Asthma Model	68
5.3.2.1 Systemic Sensitization	68
5.3.2.2 Airway Challenge	68
5.3.2.3 Administration of SRS27 to Mice	68
5.3.2.4 Serum Collection	69
5.3.2.5 Bronchoalveolar Lavage (BAL) Fluid Collection	69
5.3.2.6 Lung Sample Collection	69
5.3.2.7 Total Cell Count	70
5.3.2.8 Differential Cell Count	70
5.3.3 Histology	70
5.3.3.1 Periodic Acid Fluorescent Staining	71
5.3.3.2 Haematoxylin and Eosin Staining	71
5.3.3.3 Analysis and Scoring Criteria	71
5.3.4 Enzyme-Linked Immunosorbent Assay (ELISA)	72
5.3.4.1 Cytokine and chemokine levels in BAL fluid	72
5.3.4.2 Immunoglobulin E (IgE) level in serum	72
5.3.5 Reverse Transcription– Polymerase Chain Reaction (RT-PCR)	73
5.3.5.1 RNA extraction	73
5.3.5.2 Reverse transcription	73
5.3.5.3 Polymerase Chain Reaction	73
5.3.5.4 Gel electrophoresis	74
5.3.6 Measurement of Airway Hyper-responsiveness (AHR)	74
5.3.7 Detection of Nuclear Protein Expression in Lung	75

Samples	
5.3.7.1 Nuclear protein extraction	75
5.3.7.2 NF- $\kappa$ B Transcription Factor Assay (TransAM Assay)	76
5.3.7.3 Western Blot	76
5.3.8 Statistical Analysis	76
5.4 Results	
5.4.1 Effects of SRS27 on OVA-induced inflammatory cell recruitment in BAL fluid	77
5.4.2 Effects of SRS27 on airway cell infiltration and airway mucus production	82
5.4.3 Effects of SRS27 on cytokine levels in BAL fluid and serum IgE levels	85
5.4.4 Effects of SRS27 on lung mRNA expression of inflammatory markers	90
5.4.4.1 Effects of SRS27 on mRNA expression of chitinases in lung tissue	91
5.4.4.2 Effects of SRS27 on mRNA expression of adhesion molecules in lung tissue	92
5.4.4.3 Effects of SRS27 on mRNA expression of pro-inflammatory mediators in lung tissue	93
5.4.4.4 Effects of SRS27 on mRNA expression of cytokines in lung tissue	95
5.4.4.5 Effects of SRS27 on mRNA expression of chemokines in lung tissue	96
5.4.4.6 Effects of SRS27 on mRNA expression of oxidative stress markers in lung tissue	97
5.4.5 Effects of SRS27 on OVA-induced AHR in mice	99
5.4.6 Effects of SRS27 on the NF- $\kappa$ B signalling pathway in Lung Tissues	101
5.5 Discussion	103
5.6 Conclusion	112
<b>6 PHARMACOKINETIC PROFILE OF SRS27</b>	
6.1 Introduction	113
6.2 Materials	
6.2.1 Compounds Isolation and Synthesis	114
6.2.2 Animals	114
6.2.3 Chemicals and Reagents	114
6.2.4 Laboratories Wares and Consumables	114
6.2.5 Instrumentations	114
6.3 Methods	
6.3.1 Preparation of SRS27 for in vivo Pharmacokinetic Study	114
6.3.2 Administration of SRS27 to Mice	114
6.3.3 Sample Collection and Handling	114
6.3.4 Extraction Procedure	115
6.3.5 HPLC Analysis	115
6.3.6 Calibration Curve and Method Validation	115
6.3.7 Pharmacokinetic Analysis of SRS27	116

6.3.8 Lipinski Rule of Five	116
6.3.9 Statistical Analysis	116
6.4 Results	
6.4.1 Method Development and Validation	117
6.4.2 Pharmacokinetic Profile of SRS27 in Mouse	118
6.4.3 Lipinski's rule	121
6.5 Discussion	122
6.6 Conclusion	123
<b>7 ACUTE TOXICITY PROFILE OF SRS27</b>	
7.1 Introduction	124
7.2 Materials	
7.2.1 Compounds Isolation and Synthesis	125
7.2.2 Animals	125
7.2.3 Chemicals and Reagents	125
7.2.4 Laboratories Wares and Consumables	126
7.2.5 Instrumentations	126
7.3 Methods	
7.3.1 Peripheral Cell Count	126
7.3.2 AST, ALT and Creatinine levels	126
7.3.3 Acute Toxicity of SRS27 in Mice	126
7.3.4 Histopathological Evaluation of Liver, Lung, Kidney and Ovary	127
7.3.5 Statistical Analysis	128
7.4 Results	
7.4.1 Peripheral Cell Count	128
7.4.2 AST, ALT and Creatinine level	130
7.4.3 Body and Organ Weight Changes	131
7.4.4 Histological Changes	132
7.5 Discussions	142
7.6 Conclusion	145
<b>8 GENERAL DISCUSSION AND CONCLUSION</b>	
8.1 General Discussion	146
8.2 Conclusion	154
8.3 Future Research	155
<b>REFERENCES</b>	157
<b>APPENDICES</b>	200
<b>BIODATA OF STUDENT</b>	258
<b>LIST OF PUBLICATIONS</b>	259

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
3.1	Molecular properties of DDAG and its derivatives	45
4.1	Primers used to study biological response in A549 cells	53
5.1	Primers used to study biological response in mouse lung samples.	73
6.1	Pharmacokinetic parameters calculation.	116
6.2	Intra-day and Inter-day precision.	118
6.3	Comparison of pharmacokinetic parameters of SRS27, AGP and DDAG	120
6.4	Table summarises the pharmaceutical properties of AGP, DDAG and SRS27 according to Lipinski's rule.	121
7.1	Scoring system employed for histopathological evaluation of organs.	127
7.2	Scores of liver, kidney, lung, spleen and ovary toxicity of mice treated with various concentrations of SRS27 compared with those of the control group.	133

## LIST OF FIGURES

Figure		Page
2.1	World map of the prevalence of clinical asthma in 2004.	4
2.2	Ranking of the prevalence of current asthma symptoms in childhood with positive response to clinical asthma seen by country in 2004	5
2.3	The initiation of allergic airway inflammation by Th2 cell-mediated response.	7
2.4	NF- $\kappa$ B signalling pathway and its activated downstream genes.	12
2.5	The synthesis scheme of CysLT.	13
2.6	The role of CysLT in asthma pathogenesis.	14
2.7	The production of NO in the lung airway of an asthmatic patient.	15
2.8	Chemical structures of AGP, DDAG and its derivatives.	24
3.1	Single concentration effect of various AGP analogues on CysLT released from calcium ionophore stimulated mouse macrophages and cell viability of macrophages	36
3.2A	Dose-response effects of SRS27, DDAG, AGP and NDGA on CysLT released from calcium ionophore stimulated mouse macrophages	37
3.2B	Viability of calcium ionophore-stimulated mouse macrophages upon treatment with increasing concentration of SRS27, DDAG, AGP and NDGA	37
3.3A	Effects of AGP, DDAG, SRS27, SRS28, SRS49, SRS76 and SRS83 on NO production in RAW 264.7 stimulated by IFN- $\gamma$	39
3.3B	Effects of test agents on RAW 264.7 cell viability after 24 hr exposure to 10 U of IFN- $\gamma$	40
3.4A	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of RAW264.7	41
3.4B	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of PC3	42
3.4C	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of A549	42

3.4D	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of MCF-7	43
3.4E	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of HCT116	43
3.4F	Dose-response cytotoxic effects of AGP, DDAG and SRS27 on the viability of VERO	44
4.1	Effects of SRS27 on the NF- $\kappa$ B-activated biological response	56
4.2	DNA-binding activity of p65 nuclear factor- $\kappa$ B in nucleus of A549 cells stimulated with TNF- $\alpha$ for 5 min in the presence or absence of 30 $\mu$ M of SRS27 was determined using a TransAM p65 transcription factor ELISA kit.	57
4.3	Effects of SRS27 on TNF- $\alpha$ -induced NF- $\kappa$ B activation	58
4.4	Semi-quantitative analysis of three independent experiments of bands from figure 4.3	59
4.5	Immunoblotting of p65 level in nuclear extracts of A549 cells stimulated with TNF- $\alpha$ for 5 min in the presence and absence of 30 $\mu$ M SRS27	59
4.6	Semi-quantitative analysis of three independent experiments of bands from figure 4.5.	60
4.7	Proposed anti-inflammatory mechanism of action of AGP, DDAG and SRS27.	63
5.1	Allergen aerosol delivery system.	68
5.2	Animal sensitization, challenge and treatment schedule.	69
5.3	Lung lobes in mouse.	70
5.4	The FinePointe™ system (Buxco Research Systems, Wilmington, NC, USA).	75
5.5	Light micrographs of cell population in a saline-challenged mouse and OVA-challenged mouse stained with Liu staining.	78
5.6	Total and different inflammatory cell counts in BAL fluid of OVA-sensitized and saline-challenged (Saline) and OVA-sensitized and OVA-challenged (OVA) mice.	79
5.7	Light micrographs of cell population in BAL fluid of DMSO-treated OVA-challenged mice and OVA-challenged mice	80



treated with 0.1 mg/kg, 0.3 mg/kg, 1.0, 3.0 mg/kg of SRS27.

- 5.8 Total and differential cell counts were performed on BAL fluid obtained from vehicle control (3% DMSO) mice, and four drug treatment groups (0.1 0.3, 1.0 and 3.0 mg/kg SRS27) 24 hours after the last aerosol challenge. 81
- 5.9 Representative photomicrographs of lung sections of saline control mice, OVA-challenged mice, OVA-challenged and DMSO-treated mice, and OVA-challenged and 3.0 mg/kg SRS27-treated mice 24 hours after the last aerosol challenge. 83
- 5.10 Mean scores of inflammatory cell infiltration in three different lung samples of respective lung sections of Figure 5.9. 83
- 5.11 Representative fluorescent photomicrographs of saline control mice, OVA-challenged mice, OVA-challenged and DMSO-treated mice, and OVA-challenged and 3.0 mg/kg SRS27-treated mice 24 hours after the last aerosol challenge. 84
- 5.12 Mean scores of mucus production in three different lung samples of respective lung sections of Figure 5.11. 84
- 5.13A Level of IL-4 in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 85
- 5.13B Level of IL-5 in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 86
- 5.13C Level of IL-13 in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 86
- 5.13D Level of Eotaxin in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 87
- 5.14 Level of IFN- $\gamma$  in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 88
- 5.15 Levels of isoprostane and 8-OH-2-deoxyguanosine in BAL fluid of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA. 89



5.16	Levels of total IgE and OVA-specific IgE in mouse serum of saline control mice, OVA-challenged mice, DMSO-treated mice, and 0.1, 0.3, 1.0, and 3.0 mg/kg SRS27-treated mice measured using ELISA.	90
5.17	(A) Representative images of polymerase chain reaction products of chitinases. (B) Mean relative intensity of bands of chitinases against saline group quantified using Image J.	92
5.18	(A) Representative images of polymerase chain reaction products of adhesion molecules. (B) Mean relative intensity of bands of adhesion molecules against saline group quantified using Image J.	93
5.19	(A) Representative images of polymerase chain reaction products of inflammatory mediators. (B) Mean relative intensity of bands of inflammatory mediators against saline group quantified using Image J.	94
5.20	(A) Representative images of polymerase chain reaction products of cytokines. (B) Mean relative intensity of bands of cytokines against saline group quantified using Image J.	95
5.21	(A) Representative images of polymerase chain reaction products of chemokines. (B) Mean relative intensity of bands of chemokines against saline group quantified using Image J.	96
5.22	(A) Representative images of polymerase chain reaction products of oxidative stress markers. (B) Mean relative intensity of bands of oxidative stress markers against saline group quantified using Image J.	98
5.23	Airway resistance and dynamic compliance of mechanically ventilated mice (Saline= saline control mice, OVA= OVA-challenged mice, 3% DMSO= DMSO-treated mice and SRS27= 3.0 mg/kg SRS27-treated mice) in response to increasing concentrations of methacholine (0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg).	100
5.24	Representative images of immunoblotting of p65 level in lung nuclear protein lysate and Intensity of bands against saline group quantified using Image J.	101
5.25	Nuclear binding activity of NF- $\kappa$ B in lung tissue.	102
6.1	Representative chromatogram of (A) SRS27 (100 $\mu$ M) and (B) DDAG (50 $\mu$ M) in mobile phase (50% ACN and 50% H <sub>2</sub> O).	117
6.2	The mean plasma concentration–time profile of SRS27 after administration of a single i.p. bolus dose of 3 mg/kg to female	119

Balb/C mice.

7.1A	Peripheral blood leukocytes analysis of haematological blood profile obtained from normal control, vehicle control, and SRS27-treated non-asthmatic BALB/C mice.	128
7.1B	Peripheral blood leukocytes analysis of haematological blood profile obtained from normal control, vehicle control, and SRS27-treated non-asthmatic BALB/C mice.	129
7.2	AST and ALT level in serum of control and mice treated with 3 mg/kg of SRS27 measured during the toxicity study.	130
7.3	Creatinine level in serum of control, DMSO (3%) and mice treated with 3 mg/kg of SRS27 measured during the toxicity study.	130
7.4	Percentage normalised body weight changes relative to day 0 of control and mice treated with various doses of SRS27 during the toxicity study.	131
7.5	Relative organ weight of control mice and mice treated with various doses of SRS27 measured at the end of the toxicity study.	132
7.6	Photomicrograph of liver sections of vehicle control mice and mice treated with various doses of SRS27.	134
7.7	Photomicrograph of lung sections of vehicle control mice and mice treated with various doses of SRS27.	136
7.8a	Photomicrograph of kidneys of vehicle control mice and mice treated with various doses of SRS27.	138
7.8b	Photomicrograph of kidneys of vehicle control mice and mice treated with various doses of SRS27.	139
7.8c	Photomicrograph of kidney section of one mouse treated with 6 mg/kg of SRS27.	140
7.9	Photomicrographs of ovaries of vehicle control mice and mice treated with various doses of SRS27.	141
8.1	Proposed anti-inflammatory mechanism of action of AGP, DDAG and SRS27	149

## LIST OF ABBREVIATIONS

5-LOX	5-Lipoxygenase
8-OHdG	8-Oxo-2'-deoxyguanosine
A549	Adenocarcinomic human alveolar basal epithelial cells.
AChE	Acetylcholinesterase
AGP	Andrographolide
AHR	Airway hyperresponsiveness
AHU	Animal Holding Unit
AIRIAP	Asthma Insights and Reality in Asia Pacific
AKT	Protein Kinase B
ALT	Alanine transaminase
Al(OH) <sub>3</sub>	Aluminium hydroxide
AMCase	Acidic mammalian chitinase
AMV	Avian myeloblastosis virus
ANOVA	Analysis of variance
AP	Alkaline phosphatase
AP-1	Activator protein
ASM	Airway smooth muscle
AST	Aspartate transaminase
ATP	Adenosine triphosphate
AUC	Area under curve
B <sub>0</sub>	Maximum binding well
BAL	Bronchoalveolar lavage
BALB/C	Albino, laboratory-bred strain mice
Baso	Basophils
BCA	Bicinchoninic acid
Bcl-3	B-cell lymphoma 3-encoded
BEAS-2B	Human lung epithelial cells
BSA	Bovine serum albumin
cAMP	Cyclic adenosine monophosphate
Ca <sup>2+</sup>	Calcium ion
CARE	Centre for Animal Resources
CD4+	Cluster of differentiation 4
CDER	Centre for Drug Evaluation and Research
Cdyn	Dynamic compliance
CHMP	Committee for Medicinal Products for Human Use
Cl	Clearance
C <sub>max</sub>	Maximum concentration
CNS	Central nervous system
CO <sub>2</sub>	Carbon dioxide
COPD	Chronic obstructive pulmonary disease
COX	Cyclooxygenases
COX-2	cyclooxygenase 2
CS	Corticosteroids
CVM	Centre for Veterinary Medicine
CXC	α-chemokines
CysLT	Cysteinyl leukotriene
DDAG	14-deoxy-11,12-didehydroandrographolide
DEPC	Diethylpyrocarbonate

DMEM	Dulbecco's Modified Eagle's medium
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
DNase	Deoxyribonuclease
DPX	Digital Picture Exchange
DTT	Dithiothreitol
ECL	Enhanced chemiluminescence
ECP	Eosinophil cationic proteins
EDTA	Ethylenediaminetetraacetic acid
EGF	Epidermal growth factor
EIA	Enzyme immunoassay
ELISA	Enzyme-linked immunosorbent assay
EPO	Eosinophil peroxidase
Eos	Eosinophils
ERK	Extracellular signal-related kinase
E-selectin	Endothelial selectin
FBS	Foetal bovine serum
Fc $\epsilon$ R	High affinity IgE receptor
FDA	Food and Drug Administration
FLAP	5-lipoxygenase activating protein
Foxa2	Forkhead box $\alpha$ -2
GATA3	Trans-acting T-cell-specific transcription factor
GCCP	Good cell culture practice
GPCRs	G protein coupled receptors
G-CSF	Granulocyte colony stimulating factor
GINA	Global Initiative for Asthma
GM-CSF	Granulocyte macrophage colony stimulating factor
GR	Glucocorticoid receptors
HCl	Hydrochloride acid
HCT116	Human colon cancer cell line
HDAC2	Histone deacetylase-2
HIV	Human immunodeficiency virus
H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
H <sub>3</sub> PO <sub>4</sub>	Phosphoric acid
HPLC	High performance liquid chromatography
HRP	Horseradish peroxidase
IACUC	Institutional Animal Care and Use Committee
ICAM-1	Intercellular Adhesion Molecule 1
ICS	Inhaled corticosteroids
IFN	Interferon
IgA	Immunoglobulin A
IgE	Immunoglobulin E
IgG4	Immunoglobulin G4
IGF	Insulin-like growth factor
I $\kappa$ B	Inhibitor $\kappa$ B
IKK- $\alpha$	Inhibitor of kappaB kinase alpha
IKK- $\beta$	Inhibitor of kappaB kinase beta
IL	Interleukin
iNOS	Inducible nitric oxide synthase
i.p.	Intraperitoneal

JAK	Janus kinase
JNK	c-Jun N-terminal kinases
kDA	Kilo Dalton
$K_{el}$	Elimination rate constant
LABA	Long-acting $\beta$ 2-adrenoceptor agonists
L-NAME	L-NG-Nitroarginine Methyl Ester
Log P	Compound lipophilicity
LPS	Lipopolysaccharide
LT	Leukotriene
LTC <sub>4</sub>	Leukotriene C4
LTD <sub>4</sub>	Leukotriene D4
LTE <sub>4</sub>	Leukotriene E4
Lym	Lymphocytes
Mac	Macrophages
MAPK	Mitogen activated protein kinase
MBP	Major basic protein
MCF7	Human breast cancer cell line
Mch	Acetyl- $\beta$ -methylcholine chloride
MCP-1	Monocyte chemotactic protein-1
MMP	Matrix metalloproteinase
Mono	Monocytes
MHC	Major histocompatibility complex
MUC	Mucin
Muc5ac	Gel-forming mucin
Muc5b	Gel-forming mucin
MTT	3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide
NAG	Neoandrographolide
NDGA	Nordihydroguaiaretic acid
NEMO	NF-kappa-B essential modulator
Neu	Neutrophils
NF-kB	Nuclear factor kappa B
NLS	Nuclear localisation signal
NO	Nitric oxide
NOS	Nitric oxide synthase
NSB	Non-specific binding
NUS	National University of Singapore
ONOO-	Peroxynitrite
O <sub>2</sub> <sup>-</sup>	Superoxide anion
OVA	Ovalbumin
P	1-octanol/water partition coefficient
$\Delta P/V$	Pressure driving respiration divided by airflow
PAGE	Polyacrylamide gel electrophoresis
PBS	Phosphate buffered saline
PBS-T	PBS containing 0.1% Tween 20
PC3	Human prostate cancer cell line
PCR	Polymerase chain reaction
PDGF	Platelet-derived growth factor
PI3K	Phosphatidylinositol 3-kinase
PKAc	Protein Kinase A catalytic subunit
PKC	Protein kinase C

PVDF	Polyvinylidene difluoride
RANTES	Regulated on Activation, Normal T Cell Expressed and Secreted
RAW 264.7	Mouse leukaemic monocyte macrophage cell line
RBM	Reticular basement membrane
RBL-2H3	Rat basophilic leukaemia
RI	Airway resistance
RNA	Ribonucleic acid
RNasin	Ribonuclease inhibitor
RNase	Ribonuclease
RNS	Reactive nitrate species
RSD	Relative standard deviation
RT	Retention time
RT-PCR	Reverse transcriptase polymerase chain reaction
RTV	Real-Time Viewing
ROS	Reactive oxygen species
ROW	Relative organ weight
rpm	Revolutions per minute
RPMI	Roswell Park Memorial Institute medium
SABA	Short-acting beta2-agonists
SCG	Sodium cromoglicate
SD	Standard deviation
SDS	Sodium dodecyl sulphate
SIT	Allergen immunotherapy
SPSS	Statistical Package for Social Sciences
SOD	Superoxide dismutase
SRS27	3,19-Diacetyl-14-deoxy-11,12-didehydroandrographolide
SRS28	19-Acetyl-14-deoxy-11,12-didehydroandrographolide
SRS49	3,19-Dipropionyl-14-deoxy-11,12-didehydroandrographolide
SRS76	3,19-Benzylidene-14-deoxy-11,12-didehydroandrographolide
SRS83	3,19-(4-Chlorobenzylidene)-14-deoxy-11,12-didehydroandrographolide
SRS88	3,19-(4-Acetamidobenzylidene)andrographolide
STAT	Signal transducer and activator of transcription
T <sub>1/2</sub>	Half-life
TA	Total activity well
TAE	Tris-acetate-EDTA
T-bet	T box transcription factor
TDZD-8	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
TEMED	N, N, N', N'- tetramethylethylenediamine
TGF-β	Transforming growth factor beta
Th0	Naïve T-Helper cells
Th1	T-helper cells 1
Th2	T-helper cells 2
T <sub>max</sub>	Time to achieve C <sub>max</sub>
TMB	3,3',5,5'-tetramethylbenzidine
TNF- α	Tumour necrosis factor alpha
TNF-R	Tumour necrosis factor receptor
TRCP	β-transducin repeat-containing protein
T <sub>regs</sub>	Regulatory T cells



TSLP	Thymic stromal lymphopoietin
TTBS	Tris-Buffered Saline and Tween 20
Tween 20	Polyoxyethylene sorbitan monolaurate
URTI	Acute upper respiratory tract infection
US	United States of America
USD	United States Dollar
UV	Ultraviolet
$\Delta V/\Delta P$	Change in volume of the lung produced by a change in pressure across the lung
V	Volt
VCAM-1	Vascular cell adhesion protein 1
$V_d$	Volume of distribution
VEGF	Vascular endothelial growth factor
VERO	African green monkey kidney epithelial cells
VLA	Very late antigen
WBC	White blood cells
Ym-2	Chitinase 3-like 4
YKL-40	Chitinase 3-like 1



## CHAPTER 1

### INTRODUCTION

#### 1.1 Background of the Study

Asthma is one of the most common chronic diseases, affecting both children and adults worldwide, with increasing prevalence over the past 40 years. The reasons for this dramatic increase in asthma are not yet clear and are likely to include multiple contributing factors. There are currently 300 million people worldwide estimated to be affected by asthma (Masoli *et al.*, 2004). For decades, the number of asthmatic cases has been increasing significantly. Considering population growth and increased urbanisation, the number of asthmatic patients is expected to rise to 400 million by the year 2025. It is estimated that 1 out of 250 deaths worldwide is due to asthma attacks (Peters *et al.*, 2006).

#### 1.2 Problem Statements

Asthma is underdiagnosed and undertreated, but the symptoms usually respond well and can be controlled with inhaled corticosteroids (CS) and a short- or long-acting  $\beta_2$ -agonist (Braman, 2006). Glucocorticoids are the most effective anti-inflammatory drugs available for the treatment of many chronic inflammatory and immune diseases, including asthma, rheumatoid arthritis, inflammatory bowel disease and autoimmune diseases (Barnes, 2010). In Malaysia, the most preferred medications for 'first-line', 'second-line' and 'third-line' treatment for asthma by government doctors were inhaled short-acting beta2-agonists (SABAs), CS, and leukotriene antagonist, respectively, whereas private doctors preferred oral SABAs, inhaled CS, and oral CS, respectively (Loh and Wong, 2005). However, CS suffers from unwanted side effects and a significant proportion of patients are steroid-resistant (Adcock and Lane, 2003; Barnes, 2010). Steroid-resistant patients have symptoms consistent with asthma and show very poor or no response at all to high doses of inhaled or even systemic corticosteroids (Barnes, 2010). In addition to resistance, there has been increasing concern over the adverse effects of CS, such as osteoporosis, glaucoma, growth retardation in children and poor wound healing effects (Schacke *et al.*, 2002). Add-on therapies for asthma such as long-acting reliever inhalers, leukotriene receptor antagonists and theophylline were invented to attenuate asthma *via* other approaches; however, the effects of these treatments are not as efficacious as those of steroids.

There has been a sharp increase in economic burden associated with asthma over the last 40 years, particularly in children. Asthma can involve costs related to health care use and morbidity, including missed work and school days. The large asthma burden and continued adverse outcomes present an on-going public health challenge, including the effort to enhance the uptake of underutilised management strategies to control symptoms (Akinbami *et al.*, 2011). Approximately 300 million people worldwide currently have asthma, and its prevalence increases by 50% every decade. Although asthma is most common in developed (westernised) countries, it is becoming increasingly common in developing countries like Malaysia, which is most likely related to the increased urbanisation of communities. Despite the constant publications and guidelines from the National Asthma Education and Prevention Program to educate the public awareness on

the disease, asthma still remains poorly controlled, with annual estimated costs of up to 56 billion USD (Spangler, 2012).

### **1.3 Significance of the Study**

With the in-depth knowledge of asthma available, many new therapies for asthma have been developed. Current leading therapies for asthma rely mainly on ICS and LABAs. Despite being the most effective treatment for asthma, ICSs cause several systemic side effects. Add-on therapies that have been introduced over the past decade also either pose noticeable side effects (in the case of omalizumab) or have a narrow therapeutic index (in the case of theophylline). Thus, there is always an urgency to discover and develop a more potent and yet safer treatment for asthma. Searching for an alternative for many inflammatory diseases in natural products is the current trend, as many of the plants have yet to be exploited and studied (Lim *et al.*, 2012).

The bioactive compounds from the famous Asian herb *Andrographis paniculata* have been studied for their anticancer and anti-inflammatory properties for more than a decade (Lim *et al.*, 2012). The herb contains two main diterpenoid constituents named andrographolide (AGP) and 14-deoxy-11,12-didehydroandrographolide (DDAG). Both of the compounds were found to exhibit antiasthma effects by inhibiting inflammatory responses in an allergic mouse asthma model (Bao *et al.*, 2009; Guan *et al.*, 2011). In the present investigation, the anti-inflammatory effects and the involved pathways of a DDAG analogue which possess improved drug-like properties compared with the parent compound as new antiasthma agents were investigated.

### **1.4 HYPOTHESIS**

The new semi-synthetic andrographolide derivatives have anti-asthma activity through their inhibitory effect on NF- $\kappa$ B and related pathways.

### **1.5 OBJECTIVES OF THE STUDY**

#### **1.5.1 Main Objective:**

The aim of the study is to investigate the potential of DDAG analogues which possess improved drug-like properties compared with the parent compound as new antiasthma agents.

#### **1.5.2 Specific Objectives**

- a) To determine the inhibition of cysteinyl leukotriene and nitric oxide synthesized *in vitro* by andrographolide derivatives in mouse macrophage models.
- b) To determine the effect of SRS27 on cell signalling pathway in A549 cells associated with anti-asthmatic effect.
- c) To determine the efficacy of SRS27 in a mouse asthma model.
- d) To evaluate toxicity and pharmacokinetics of SRS27 in mice.

## REFERENCES

Aaronson, D.W. (2006). The "black box" warning and allergy drugs. *Journal of Allergy and Clinical Immunology*. 117(1): 40-44.

Abdala-Valencia, H., Earwood, J., Bansal, S., Jansen, M., Babcock, G., Garvy, B., Wills-Karp, M., Cook-Mills, J.M. (2007). Nonhematopoietic, N.A.D.P.H. oxidase regulation of lung eosinophilia and airway hyperresponsiveness inexperimentally induced asthma. *American Journal of Physiology - Lung Cellular and Molecular Physiology*. 292: L1111-1125.

Abu-Ghefreh, A.A., Canatan, H., Ezeamuzie, C.I. (2009). In vitro and in vivo anti-inflammatory effects of andrographolide. *International Immunopharmacology*. 9(3): 313-318.

Acharya, M., Borland, G., Edkins, A.L., Maclellan, L.M., Matheson, J., Ozanne, B.W., Cushley, W. (2010). CD23/FcεRII: molecular multi-tasking. *Clinical and Experimental Immunology*. 162(1): 12-23.

Adcock, I.M., Lane, S.J. (2003). Corticosteroid-insensitive asthma: molecular mechanisms. *Journal of Endocrinology*. 178(3): 347-355.

Adcock, I.M., Caramori, G., Chung, K.F. (2008). New targets for drug development in asthma. *Lancet*. 372(9643): 1073-1087.

Adcock, I.M., Barnes, P.J. (2008). Molecular mechanisms of corticosteroid resistance. *Chest*. 134: 394-401.

Afshar, R., Medoff, B.D., and Luster, A.D. (2008). Allergic asthma: a tale of many T cells. *Clinical and Experimental Allergy*. 38: 1847-1857.

Ajaya, K., Sridevi, K., Vijaya, K., Nanduri, S., Rajagopal, S. (2004). Anticancer and immunostimulatory compounds from *Andrographis paniculata*. *Journal of Ethnopharmacology*. 92: 291-295.

Akbar, S. (2011). *Andrographis paniculata*: a review of pharmacological activities and clinical effects. *Alternative Medicine Review*. 16(1): 66-77.

Akbarsha, M.A., Murugaian, P. (2000). Aspects of the male reproductive toxicity/male antifertility property of andrographolide in albino rats: effect on the testis and the cauda epididymidal spermatozoa. *Phytotherapy Research*. 14(6): 432-435.

Akhood, B.A., Gupta, S.K., Dhaliwal, G., Srivastava, M., Gupta, S.K. (2011). Virtual screening of specific chemical compounds by exploring *E.coli* NAD<sup>+</sup>-dependent DNA ligase as a target for antibacterial drug discovery. *Journal of Molecular Modelling*. 17: 265-273.

Akinbami, L.J., Moorman, J.E., Liu, X. (2011). Asthma prevalence, health care use, and mortality: United States, 2005-2009. *COPD*. 8(6): 400-407.

Aktan, F. (2004). iNOS-mediated nitric oxide production and its regulation. *Life Sciences*. 75(6): 639-653.

Ala, A., Dhillon, A.P., Hodgson, H.J. 2003. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. *International Journal of Experimental Pathology*. 84(1): 1-16.

Anderson, H.R. (2005). Prevalence of asthma. *British Medical Journal*. 330(7499): 1037-1038.

Aromdee, C. (2012). Modifications of andrographolide to increase some biological activities: a patent review (2006 - 2011). *Expert Opinion on Therapeutic Patents*. 22(2): 169-180.

Ashutosh, K. (2000). Nitric oxide and asthma: a review. *Current Opinion in Pulmonary Medicine*. 6(1): 21-25.

Aujla, S.J., Dubin, P.J., Kolls, J.K. (2007). Th17 cells and mucosal host defense. *Seminars in Immunology*. 19(6): 377-382.

Avila, P.C. (2007). Does anti-IgE therapy help in asthma? Efficacy and controversies. *Annual Review of Medicine*. 58: 185-203.

Bahari, M.B., Mohd Nur, M., Rahman, F.A.B. (2003). A knowledge of asthma in school children: A survey among primary school teachers. *Singapore Medical Journal*. 44: 131-135.

Bakri, R., Mohd Said, N., Mohan, J., (1999). National Health and Morbidity Survey. *Ministry of Health, Malaysia*.

Baldi, L., Brown, K., Franzoso, G., Siebenlist, U. (1996). Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. *Journal of Biological Chemistry*. 271(1): 376-379.

Bandeira-Melo, C., J. C. Hall, J. F. Penrose, and P. F. Weller. (2002). Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. *Journal of Allergy and Clinical Immunology*. 109: 975-979.

Bao, Z., Lim, S., Liao, W., Lin, Y., Thiemermann, C., Leung, B.P., Wong, W.S. (2007). Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. *American Journal of Respiratory and Critical Care Medicine*. 176(5): 431-438.

Bao, Z., Guan, S., Cheng, C., Wu, S., Wong, S.H., Kemeny, D.M., Leung, B.P., Wong, W.S. (2009). A novel antiinflammatory role for andrographolide in asthma via inhibition



of the nuclear factor-kappaB pathway. *American Journal of Respiratory and Critical Care Medicine*. 179(8): 657-665.

Bara, I., Ozier, A., Girodet, P.O., Carvalho, G., Cattiaux, J., Begueret, H., Thumerel, M., Ousova, O., Kolbeck, R., Coyle, A.J., Woods, J., Tunon de Lara, J.M., Marthan, R., Berger, P. (2012). Role of YKL-40 in bronchial smooth muscle remodeling in asthma. *American Journal of Respiratory and Critical Care Medicine*. 185(7): 715-722.

Baraldi, E., Ghironi, L., Piovani, V., Carraro, S., Ciabattini, G., Barnes, P.J., Montuschi, P. (2003). Increased exhaled 8-isoprostane in childhood asthma. *Chest*. 124(1): 25-31.

Barnes, P.J., Liew, F.Y. (1995). Nitric oxide and asthmatic inflammation. *Immunology Today*. 16(3): 128-130.

Barnes, P.J., Adcock, I.M. (1997). NF-kappa B: a pivotal role in asthma and a new target for therapy. *Trends in Pharmacological Sciences*. 18(2): 46-50.

Barnes, P.J. (2003). Theophylline: new perspectives for an old drug. *American Journal of Respiratory and Critical Care Medicine*. 167: 813-818.

Barnes, P.J. (2004). New drugs for asthma. *Discovery Medicine*. 4(24): 421-426.

Barnes, P.J. (2005) Molecular mechanisms and cellular effects of glucocorticosteroids. *Immunology and Allergy Clinics of North America*. 25(3): 451-468.

Barnes, P.J. (2006a) How corticosteroids control inflammation: Quintiles Prize Lecture 2005. *British Journal of Pharmacology*. 148(3): 245-254.

Barnes, P.J. (2006b) Corticosteroid effects on cell signalling. *European Respiratory Journal*. 27(2): 413-426.

Barnes, P.J. (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. *Journal of Clinical Investigation*. 118(11): 3546-3556.

Barnes, P.J., Dweik, R.A., Gelb, A.F., Gibson, P.G., George, S.C., Grasemann, H., Pavord, I.D., Ratjen, F., Silkoff, P.E., Taylor, D.R., Zamel, N. (2010). Exhaled nitric oxide in pulmonary diseases: a comprehensive review. *Chest*. 138(3): 682-692.

Barnes, P.J. (2010). Mechanisms and resistance in glucocorticoid control of inflammation. *Journal of Steroid Biochemistry and Molecular Biology*. 120(2-3): 76-85.

Barnes, P.J. (2011). Pathophysiology of allergic inflammation. *Immunological Reviews*. 242(1): 31-50.

Bateman, E.D., Hurd, S.S., Barnes, P.J., Bousquet, J., Drazen, J.M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S.E., Pizzichini, E., Sullivan, S.D., Wenzel,

S.E., Zar, H.J. (2008). Global strategy for asthma management and prevention: GINA executive summary. *European Respiratory Journal*. 31(1): 143-178.

Bentley, A.M., Meng, Q., Robinson, D.S., Hamid, Q., Kay, A.B., Durham, S.R. (1993a) Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. *American Journal of Respiratory Cell and Molecular Biology*. 8: 35-42.

Bentley, A.M., Durham, S.R., Robinson, D.S., Menz, G., Storz, C., Cromwell, O., Kay, A. B., Wardlaw, A.J. (1993b). Expression of endothelial and leukocyte adhesion molecules intercellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. *Journal of Allergy and Clinical Immunology*. 92: 857-868.

Bhandari, V., Choo-Wing, R., Homer, R.J., Elias, J.A. (2007). Increased hyperoxia-induced mortality and acute lung injury in IL-13 null mice. *Journal of Immunology*. 178(8): 4993-5000.

Birrell, M.A., Hardaker, E., Wong, S., McCluskie, K., Catley, M., De Alba, J., Newton, R., Haj-Yahia, S., Pun, K.T., Watts, C.J., Shaw, R.J., Savage, T.J., Belvisi, M.G. (2005). Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. *American Journal of Respiratory and Critical Care Medicine*. 172: 962-971.

Birkett, D.J. (2004). *Pharmacokinetics Made Easy*. Australia: McGraw-Hill Australia Pty Limited.

Boehm, U., Klamp, T., Groot, M., Howard, J.C. (1997). Cellular responses to interferon-gamma. *Annual Review of Immunology*. 15: 749-795.

Boot, R.G., Bussink, A.P., Verhoek, M., de Boer, P.A., Moorman, A.F., Aerts, J.M. (2005). Marked differences in tissue-specific expression of chitinases in mouse and man. *Journal of Histochemistry and Cytochemistry*. 53(10): 1283-1292.

Booth, B.W., Adler, K.B., Bonner, J.C., Tournier, F., Martin, L.D. (2001). Interleukin-13 induces proliferation of human airway epithelial cells in vitro via a mechanism mediated by transforming growth factor-alpha. *American Journal of Respiratory Cell and Molecular Biology*. 25(6): 739-743.

Borish, L.C., Nelson, H.S., Lanz, M.J., Claussen, L., Whitmore, J.B., Agosti, J.M., Garrison, L. (1999). Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. *American Journal of Respiratory and Critical Care Medicine*. 160(6): 1816-1823.

Boroujerdi, M. (2001). *Pharmacokinetics: principle and applications*. McGraw-Hill. Medical Pub. Division.

Boushey, H.A. (1982). Bronchial hyperreactivity to sulfur dioxide: physiologic and political implications. *Journal of Allergy and Clinical Immunology*. 69(4): 335-338.

Bouzigon, E., Monier, F., Boussaha, M., Le Moual, N., Huyvaert, H., Matran, R., Letort, S., Bousquet, J., Pin, I., Lathrop, M., Kauffmann, F., Demenais, F., Nadif, R.; EGEA, Cooperative Group. (2012). Associations between nitric oxide synthase genes and exhaled NO-related phenotypes according to asthma status. *PLoS One*. 7(5): e36672.

Boyce, J.A., Austen, K.F. (2005). No audible wheezing: nuggets and conundrums from mouse asthma models. *Journal of Experimental Medicine*. 201(12): 1869-1873.

Boyer, L., Plantier, L., Dagouassat, M., Lanone, S., Goven, D., Caramelle, P., Berrehar, F., Kerbrat, S., Dinh-Xuan, A.T., Crestani, B., Le Gouvello, S., Boczkowski, J. (2011). Role of nitric oxide synthases in elastase-induced emphysema. *Lab Investigation*. 91(3): 353-362.

Bradding, P., Roberts, J.A., Britten, K.M., Montefort, S., Djukanovic, R., Mueller, R., Heusser, C.H., Howarth, P.H., Holgate, S.T. (1994). Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. *American Journal of Respiratory Cell and Molecular Biology*. 10: 471-480.

Braman, S.S. (2006). The global burden of asthma. *Chest*. 130(1): 4S-12S.

Brightling, C., Berry, M., Amrani, Y. (2008). Targeting TNF- $\alpha$ : a novel therapeutic approach for asthma. *Journal of Allergy and Clinical Immunology*. 121: 5-10.

Brightling, C.E., Pavord, I.D. (2004). Eosinophils in asthma and airway hyperresponsiveness. *American Journal of Respiratory and Critical Care Medicine*. 169(1): 131-132

Broide, D.H., Lawrence, T., Doherty, T., Cho, J.Y., Miller, M., McElwain, K., McElwain, S., Karin, M. (2005). Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium. *Proceedings of the National Academy of Sciences*. 102(49): 17723-17728.

Brusasco, V. (2006). Reducing cholinergic constriction: the major reversible mechanism in COPD. *European Respiratory Review*. 15(99): 32-36.

Bureau, F., Delhalle, S., Bonizzi, G., Fiévez, L., Dogné, S., Kirschvink, N., Vanderplasschen, A., Merville, M.P., Bours, V., Lekeux, P. (2000). Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. *Journal of Immunology*. 165(10): 5822-5830.

Buss, H., Dorrie, A., Schmitz, M.L., Hoffmann, E., Resch, K., Kracht, M. (2004). Constitutive and interleukin-1-inducible phosphorylation of p65 NF- $\kappa$ B at serine



536 is mediated by multiple protein kinases including I $\kappa$ B kinase (IKK)- $\alpha$ , IKK $\beta$ , IKK $\epsilon$ , TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. *Journal of Biological Chemistry*. 279: 55633-55643.

Busse, W.W., Lemanske, R.F. (2004). Management of asthma exacerbations. *Thorax*. 59(7): 545-546.

Busse, W.W., Morgan, W.J., Gergen, P.J., Mitchell, H.E., Gern, J.E., Liu, A.H., Gruchalla, R.S., Kattan, M., Teach, S.J., Pongratic, J.A., Chmiel, J.F., Steinbach, S.F., Calatroni, A., Togias, A., Thompson, K.M., Szefer, S.J., Sorkness, C.A. (2011). Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *New England Journal of Medicine*. 364(11): 1005-1015.

Caceres, D.D., Hancke, J.L., Burgos, R.A., Sandberg, F., Wikman, G.K. (1999). Use of visual analogue scale measurements (VAS) to assess the effectiveness of standardized *Andrographis paniculata* extract SHA-10 in reducing the symptoms of common cold. A randomized double blind-placebo study. *Phytomedicine*. 6: 217-223.

Calabrese, C., Berman, S.H., Babish, J.G., Ma, X., Shinto, L., Dorr, M., Wells, K., Wenner, C.A., Standish, L.J. (2000). A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytotherapy Research*. 14(5): 333-338.

Calhoun, W.J., Reed, H.E., Moest, D.R., Stevens, C.A. (1992). Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. *American Review of Respiratory Disease*. 145: 317-325.

Calhoun, W.J., Jarjour, N.N., Gleich, G.J., Stevens, C.A., Busse, W.W. (1993). Increased airway inflammation with segmental versus aerosol antigen challenge. *American Review of Respiratory Disease*. 147(6):1465-1471.

Caramori, G., Papi, A. (2004). Oxidants and asthma. *Thorax*. 59(2): 170-173.

Chakir, J., Shannon, J., Molet, S., Fukakusa, M., Elias, J., Laviolette, M., Boulet, L.P., Hamid, Q. (2003). Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF- $\beta$ , IL-11, IL-17, and type I and type III collagen expression. *Journal of Allergy and Clinical Immunology*. 111(6): 1293-1298.

Chan, P.W., Hussain, S., Ghani, N.H., Debruyne, J.A., Liam, C.K. (2002). The direct cost of treating bronchial asthma in a teaching hospital in Malaysia. *Southeast Asian Journal of Tropical Medicine and Public Health*. 33(3): 600-603.

Chandrasekaran, C.V., Thiyagarajan, P., Deepak, H.B., Agarwal, A. (2011). In vitro modulation of LPS/calcimycin induced inflammatory and allergic mediators by pure

compounds of *Andrographis paniculata* (King of bitters) extract. *International Immunopharmacology*. 11(1): 79-84.

Chang, J., Zhang, R.M., Zhang, Y., Chen, Z.B., Zhang, Z.M., Xu, Q., Yang, Y.P., Long, Y.Y., Liu, L.L., Cai, H.Y., Gao, J., Lu, N., Mao, B., Wang, L., Li, T.Q. (2008). Andrographolide drop-pill in treatment of acute upper respiratory tract infection with external wind-heat syndrome: a multicenter and randomized controlled trial. *Zhong Xi Yi Jie He Xue Bao*. 6(12): 1238-1245.

Chao, C.Y., Lii, C.K., Tsai, I.T., Li, C.C., Liu, K.L., Tsai, C.W., Chen, H.W. (2011). Andrographolide inhibits ICAM-1 expression and NF- $\kappa$ B activation in TNF- $\alpha$ -treated EA.hy926 cells. *Journal of Agricultural and Food Chemistry*. 59(10): 5263-5271.

Chao, W.W., Lin, B.F. (2010a). Isolation and identification of bioactive compounds in *Andrographis paniculata* (Chuanxinlian). *Chinese Medical Journal*. 5: 17.

Chao, W.W., Kuo, Y.H., Lin, B.F. (2010b). Anti-inflammatory activity of new compounds from *Andrographis paniculata* by NF-kappaB transactivation inhibition. *Journal of Agricultural and Food Chemistry*. 58(4):2505-2512.

Chapman, K.R., Cartier, A., Hébert, J., McIvor, R.A., Schellenberg, R.R. (2006). The role of omalizumab in the treatment of severe allergic asthma. *Canadian Respiratory Journal*. 13(Suppl B): 1B-9B.

Chen, L.F., Greene, W.C. (2003). Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. *Journal of Molecular Medicine (Berlin)*. 81(9): 549-557.

Chen, L.F., Williams, S.A., Mu, Y., Nakano, H., Duerr, J.M., Buckbinder, L., Greene, W.C. (2005). NF-kappaB RelA phosphorylation regulates RelA acetylation. *Molecular and Cellular Biology*. 25(18): 7966-7975.

Chen, J.X., Xue, H.J., Ye, W.C., Fang, B.H., Liu, Y.H., Yuan, S.H., Yu, P., Wang, Y.Q. (2009). Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. *Biological and Pharmaceutical Bulletin*. 32(8): 1385-1391.

Chen, L.L., Wang, Z.H. (2010). Investigation of basic physical and chemical properties of andrographolide. *Pharmacy Today*, 20(1): 41-43.

Chen, H.W., Lin, A.H., Chu, H.C., Li, C.C., Tsai, C.W., Chao, C.Y., Wang, C.J., Lii, C.K., Liu, K.L. (2011). Inhibition of TNF- $\alpha$ -Induced Inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway. *Journal of Natural Product*. 74(11): 2408-2413.

Cheng, G., Arima, M., Honda, K., Hirata, H., Eda, F., Yoshida, N., Fukushima, F., Ishii, Y., Fukuda, T. (2002). Anti-interleukin-9 antibody treatment inhibits airway

inflammation and hyperreactivity in mouse asthma model. *American Journal Respiratory and Critical Care Medicine*. 166(3): 409-416.

Cherry, W.B., Yoon, J., Bartemes, K.R., Iijima, K., Kita, H. (2008). A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. *Journal of Allergy and Clinical Immunology*. 121(6): 1484-1490.

Chibana, K., Ishii, Y., Asakura, T., Fukuda, T. (2003). Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. *Journal of Immunology*. 170(8): 4290-4295.

Chibana, K., Trudeau, J.B., Mustovich, A.T., Hu, H., Zhao, J., Balzar, S., Chu, H.W., Wenzel, S.E. (2008). IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. *Clinical and Experimental Allergy*. 38(6): 936-946.

Chiou, T.J., Zhang, J., Ferrans, V.J., Tzeng, W.F. (1997). Cardiac and renal toxicity of menadione in rat. *Toxicology*. 124(3): 193-202.

Chiou, W.F., Chen, C.F., Lin, J.J. (2000). Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. *British Journal of Pharmacology*. 129(8): 1553-1560.

Cho, J.Y. (2011). Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. *Korean Journal of Internal Medicine*. 26(4): 367-383.

Choon, S. P., Sang, M. L., Sung, W. C., Uh, S., Hyeon, T. K., and Yong, H. K. (1993). Interleukin-2 and soluble interleukin-2 receptor in Bronchoalveolar lavage fluid from patients with bronchial asthma. *Chest*. 106: 400-406.

Chopra, A., Ferreira-Alves, D.L., Sirois, P., Thirion, J.P. (1992). Cloning of the guinea pig 5-lipoxygenase gene and nucleotide sequence of its promoter. *Biochemical and Biophysical Research Communications*. 185(2): 489-495.

Choi, I.W., Kim, D.K., Ko, H.M., Lee, H.K. (2004). Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. *International Immunopharmacology*. 4(14): 1817-1828.

Chow, Y.L., Lee, K.H., Vidyadaran, S., Lajis, N.H., Akhtar, M.N., Israf, D.A., Syahida, A. (2012). Cardamonin from *Alpinia rafflesiana* inhibits inflammatory responses in IFN- $\gamma$ /LPS-stimulated BV2 microglia via NF- $\kappa$ B signalling pathway. *International Immunopharmacology*. 12(4): 657-665.

Christofidou-Solomidou, M., Murphy, G.F., Albelda, S.M. (1996). Induction of E-selectin-dependent leukocyte recruitment by mast cell degranulation in human skin grafts transplanted on SCID mice. *American Journal of Pathology*. 148(1): 177-188.

Christopherson, K.S., Brecht, D.S. (1997). Nitric oxide in excitable tissues: physiological roles and disease. *Journal of Clinical Investigation*. 100(10): 2424-2429.

Chupp, G.L., Lee, C.G., Jarjour, N., Shim, Y.M., Holm, C.T., He, S., Dziura, J.D., Reed, J., Coyle, A.J., Kiener, P., Cullen, M., Grandsaigne, M., Dombret, M.C., Aubier, M., Pretolani, M., Elias, J.A. (2007). A chitinase-like protein in the lung and circulation of patients with severe asthma. *New England Journal of Medicine*. 357(20): 2016-2027.

Clark, I.A. (2007). How TNF was recognized as a key mechanism of disease. *Cytokine Growth Factor Reviews*. 18(3-4): 335-343.

Cohn, Z.A. (1978). Activation of mononuclear phagocytes: fact, fancy, and future. *Journal of Immunology*. 121(3): 813-816.

Cohn, L., Elias, J.A., Chupp, G.L. (2004). Asthma: mechanisms of disease persistence and progression. *Annual Review of Immunology*. 22: 789-815.

Collart, M.A., Baeuerle, P., Vassalli, P. (1990). Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. *Molecular and Cellular Biology*. 10(4): 1498-1506.

Conti, P., DiGiacchino, M. (2001). MCP-1 and RANTES are mediators of acute and chronic inflammation. *Allergy and Asthma Proceedings*. 22(3): 133-137.

Coon, J.T., Ernst, E. (2004). *Andrographis paniculata* in the treatment of upper respiratory tract infections: A systematic review of safety and efficacy. *Planta Medica*. 70: 293-298.

Corren, J. (2012). Inhibition of interleukin-5 for the treatment of eosinophilic diseases. *Discovery Medicine*. 13(71): 305-312.

Corren, J. (2013). Anti-interleukin-13 antibody therapy for asthma: one step closer. *European Respiratory Journal*. 41(2): 255-256.

Coussens, L.M., Werb, Z. (2002). Inflammation and cancer. *Nature*. 420(6917): 860-867.

Coyle, A.J., Ackerman, S.J., Irvin, C.G. (1993). Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. *American Review of Respiratory Disease*. 147(4): 896-900.

Creticos, P., Burk, J., Smith, L., Comp, R., Norman, P., Findlay, S. (1995). The use of twice daily nedocromil sodium in the treatment of asthma. *Journal of Allergy and Clinical Immunology*. 95(4): 829-836.



Cui, L., Qiu, F., Wang, N., Yao, X. (2004). Four new andrographolide metabolites in human urine. *Chemical and Pharmaceutical Bulletin (Tokyo)*. 52(6): 772-775.

Cui, L., Qiu, F., Yao, X. (2005). Isolation and identification of seven glucuronide conjugates of andrographolide in human urine. *Drug Metabolism and Disposition*. 33(4): 555-562.

Cunico, W., Gomes, C.R.B., Ferreira, M.L.G., Ferreira, T.G., Cardinot, D., de Souza, M.V.N., Lourenco, M. (2011). Synthesis and antimycobacterial activity of novel amino alcohol derivatives. *European Journal of Medicinal Chemistry*. 46: 974-978.

Dahl, R., Larsen, B.B., Venge, P. (2002). Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. *Respiratory Medicine*. 96(6): 432-438.

Das, B., Chowdhury, C., Kumar, D., Sen, R., Roy, R., Das, P., Chatterjee, M. (2010). Synthesis, cytotoxicity, and structure-activity relationship (SAR) studies of andrographolide analogues as anti-cancer agent. *Bioorganic and Medicinal Chemistry Letters*. 20: 6947-6950.

Das, J., Chen, C.H., Yang, L., Cohn, L., Ray, P., Ray, A. (2001). A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. *Nature Immunology*. 2(1): 45-50.

Davies, B., Brooks, G., Devoy, M. (1998). The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. *Respiratory Medicine*. 92: 256-263.

De Monchy, J.G., Kauffman, H.F., Venge, P., Koeter, G.H., Jansen, H.M., Sluiter, H.J., De Vries, K. (1985). Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. *American Review of Respiratory Disease*. 131(3): 373-376.

Defrance, T., Carayon, P., Billian, G., Guillemot, J.C., Minty, A., Caput, D., Ferrara, P. (1994). Interleukin 13 is a B cell stimulating factor. *Journal of Experimental Medicine*. 179(1): 135-143.

Deng, W.L. (1978a). Outline of current clinical and pharmacological research on *Andrographis paniculata* in China. *Newsletters of Chinese Herbal Medicine*. 10: 27-31.

Deng, W.L. (1978b). Preliminary studies on the pharmacology of the *Andrographis* product dihydroandrographolide sodium succinate. *Newsletters of Chinese Herbal Medicine*. 8: 26-28.

Desmet, C., Gosset, P., Pajak, B., Cataldo, D., Bentires-Alj, M., Lekeux, P., Bureau, F. (2004). Selective blockade of NF- $\kappa$ B activity in airway immune cells inhibits the effector phase of experimental asthma. *Journal of Immunology*. 173(9): 5766-5775.

Diaz-Guzman, E., Khosravi, M., Mannino, D.M. (2011). Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. *National Health Statistics Report*. (32): 1-14.

Dominguez, F., Yáñez-Mó, M., Sanchez-Madrid, F., Simón, C. (2005). Embryonic implantation and leukocyte transendothelial migration: different processes with similar players? *FASEB Journal*. 19(9): 1056-1060.

Donnelly, L.E., Barnes, P.J. (2002). Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*. 26(1): 144-151.

Dostert, A., Heinzl, T. (2004). Negative glucocorticoid receptor response elements and their role in glucocorticoid action. *Current Pharmaceutical Design*. 10(23): 2807-2816.

Dubucquoi, S., Desreumaux, P., Janin, A., Klein, O., Goldman, M., Tavernier, J., Capron, A., Capron, M. (1994). Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. *Journal of Experimental Medicine*. 179(2): 703-708.

Ebdrup, L., Krog, J., Granfeldt, A., Larsen, P.O., Vestergaard, C., Hokland, M., Tønnesen, E. (2008). Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation. *Acta Pathologica, Microbiologica et Immunologica Scandinavica*. 116(5): 352-360.

Eddershaw, P.J., Beresford, A.P., Bayliss, M.K. (2000). ADME/PK as part of a rational approach to drug discovery. *Drug Discovery Today*. 5(9): 409-414.

Efremov, R.G., Chugunov, A.O., Pyrkov, T.V., Priestle, J.P., Arseniev, A.S., Jacoby, E. (2007). Molecular lipophilicity in protein modeling and drug design. *Current Medicinal Chemistry*. 14(4): 393-415.

Elias, J.A., Lee, C.G., Zheng, T., Ma, B., Homer, R.J., Zhu, Z. (2003). New insights into the pathogenesis of asthma. *Journal of Clinical Investigation*. 111(3): 291-297.

Elias, J.A., Homer, R.J., Hamid, Q., Lee, C.G. (2005). Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. *Journal of Allergy and Clinical Immunology*. 116(3): 497-500.

Eöry, M.L., Zanuzzi, C.N., Fuentealba, N.A., Sguazza, G.H., Gimeno, E.J., Galosi, C.M., Barbeito, C.G. (2013). Effects of Different Anesthetics in the Murine Model of EHV-1 Infection. *Veterinary Pathology*. [Epub ahead of print]

Eugene, L., Prakash, S., Manavalan, R. (2011). Acute toxicity studies of Andrographolide. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2(3): 547-552.

Eum, S.Y., Maghni, K., Hamid, Q., Campbell, H., Eidelman, D.H., Martin, J.G. (2003). Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. *American Journal of Respiratory Cell and Molecular Biology*. 28(1):25-32.

European Medicine Agency, Science Medicine Health, Guideline on bioanalytical method; Committee for Medicinal Products for Human Use (CHMP): London, 2011.

Evans, D.J., Taylor, D.A., Zetterstrom, O., Chung, K.F., O'Connor, B.J., Barnes, P.J. (1997). A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. *New England Journal of Medicine*. 337: 1412-1418.

Feng, N., Lugli, S.M., Schnyder, B., Gauchat, J.F., Graber, P., Schlagenhauf, E., Schnarr, B., Wiederkehr-Adam, M., Duschl, A., Heim, M.H., Lutz, R.A., Moser, R. (1998). The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor alpha2. *Lab Investigation*. 78(5): 591-602.

Finkelman, F.D., Wills-Karp, M. (2008). Usefulness and optimization of mouse models of allergic airway disease. *Journal of Allergy and Clinical Immunology*. 121(3): 603-606.

Finotto, S., Neurath, M.F., Glickman, J.N., Qin, S., Lehr, H.A., Green, F.H., Ackerman, K., Haley, K., Galle, P.R., Szabo, S.J., Drazen, J.M., De Sanctis, G.T., Glimcher, L.H. (2002). Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. *Science*. 295(5553): 336-338.

Forst, B., Hansen, M.T., Klingelhöfer, J., Møller, H.D., Nielsen, G.H., Grum-Schwensen, B., Ambartsumian, N., Lukanidin, E., Grigorian, M. Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. *PLoS One*. 5(4):e10374.

Fregonese, L., Silvestri, M., Sabatini, F., Rossi, G.A. (2002). Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. *Clinical and Experimental Allergy*. 32(5): 745-750.

Fortier, A.H., Hoover, D.L., Nacy, C.A. (1982). Intracellular replication of *Leishmania tropica* in mouse peritoneal macrophages: amastigote infection of resident cells and inflammatory exudate macrophages. *Infection and Immunity*. 38(3): 1304-1308.

Galli, S.J., Grimaldeston, M., Tsai, M. (2008). Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nature Reviews Immunology*. 8(6): 478-486.

Gauvreau, G.M., Hessel, E.M., Boulet, L.P., Coffman, R.L., O'Byrne, P.M. (2006). Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. *American Journal of Respiratory Critical and Care Medicine*. 174(1): 15-20



Gelb, A.F., Barnes, P.J., George, S.C., Ricciardolo, F.L., DiMaria, G., Zamel, N. (2012). Review of exhaled nitric oxide in chronic obstructive pulmonary disease. *Journal of Breath Research*. 6(4): 047101.

Georas, S.N., Liu, M.C., Newman, W., Beall, L.D., Stealey, B.A., Bochner, B.S. (1992). Altered adhesion molecule expression and endothelial cell activation accompany the recruitment of human granulocytes to the lung after segmental antigen challenge. *American Journal of Respiratory Cell and Molecular Biology*. 7(3): 261-269.

Ghosh, S., Erzurum, S.C. (2011). Nitric oxide metabolism in asthma pathophysiology. *Biochimica et Biophysica Acta*. 1810(11): 1008-1016.

Ghosh, S., Janocha, A.J., Aronica, M.A., Swaidani, S., Comhair, S.A., Xu, W., Zheng, L., Kaveti, S., Kinter, M., Hazen, S.L., Erzurum, S.C. (2006). Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. *Journal of Immunology*. 176: 5587-5597.

Ghosh, S., Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. *Cell*. 109: S81-96.

Giustarini, D., Dalle-Donne, I., Tsikas, D., Rossi, R. (2009). Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. *Critical Reviews in Clinical Laboratory Sciences*. 46(5-6): 241-281.

Goh, F.Y., Upton, N., Guan, S., Cheng, C., Shanmugam, M.K., Sethi, G., Leung, B.P., Wong, W.S. (2012). Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-kB. *European Journal of Pharmacology*. 679(1-3):109-116.

Goto, K., Chiba, Y., Misawa, M. (2009). IL-13 induces translocation of NF-kappaB in cultured human bronchial smooth muscle cells. *Cytokine*. 46(1): 96-99.

Gould, H.J., Sutton, B.J. (2008) IgE in allergy and asthma today. *Nature Review Immunology*. 8(3): 205-217.

Grant, J.A., Nicodemus, C.F., Findlay, S.R., Glovsky, M.M., Grossman, J., Kaiser, H., Meltzer, E.O., Mitchell, D.Q., Pearlman, D., Selner, J., *et al.* (1995). Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 95(5): 923-932.

Gratziau, C., Carroll, M., Montefort, S., Teran, L., Howarth, P.H., Holgate, S.T. (1996). Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. *American Journal of Respiratory and Critical Care Medicine*. 153(2): 515-520.

Greiff, L., Erjefalt, I., Svensson, C., Wollmer, P., Alkner, U., Andersson, M., Persson, C.G. (1993). Plasma exudation and solute absorption across the airway mucosa. *Clinical Physiology*. 13(3): 219-233.

Gruner, S., Liebenthal, C., Heusser, C., Brinkmann, V., Zwirner, A., Reinicke, C., Harnack, K., Sönnichsen, N., Volk, H.D. (1991). The influence of interferon-gamma and interleukin-4 on IgE production in B lymphocytes of patients with atopic dermatitis. A possible criterion for selection of patients for interferon therapy. *Acta Dermato-Venereologica*. 71(6): 484-487.

Guan, S.P., Mok, Y.K., Koo, K.N., Chu, K.L., Wong, W.S. (2009). Chitinases: biomarkers for human diseases. *Protein and Peptide Letters*. 16(5): 490-498.

Guan, S.P., Kong, L.R., Cheng, C., Lim, J.C., Wong, W.S. (2011). Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue of andrographolide, in allergic airway inflammation. *Journal of Natural Product*. 74(6): 1484-1490.

Guan, S.P. (2012). *Effects of Andrographolide and 14-Deoxy-11,12-didehydroandrographolide in Obstructive Respiratory Disease Mouse Models*. Published doctoral dissertation, National University of Singapore, Singapore.

Guan, S.P., Tee, W., Ng, D.S., Chan, T.K., Peh, H.Y., Ho, W.E., Cheng, C., Mak, J.C., Wong, W.S. (2013). Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. *British Journal of Pharmacology*. 168(7): 1707-1718.

*Guidance for Industry, M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals*; U.S. Department of Health and Human Services, Food and Drug Administration Centre, Centre for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER): Fishers Lane, Rockville, 1997.

*Guidance for Industry, Bioanalytical Method Validation*; U.S. Department of Health and Human Services, Food and Drug Administration Centre, Centre for Drug Evaluation and Research (CDER) and Centre for Veterinary Medicine (CVM): Fishers Lane, Rockville, 2001.

*Guidance for Industry, Single Dose Acute Toxicity Testing for Pharmaceuticals*; Center for Drug Evaluation and Research (CDER): Fishers Lane, Rockville, 1996.

Guill, M.F. (2004). Asthma update: clinical aspects and management. *Pediatrics in Review*. 25(10): 335-344.

Guo, C.B., Liu, M.C., Galli, S.J., Bochner, B.S., Kagey-Sobotka, A., Lichtenstein, L.M. (1994). Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. *American Journal of Respiratory Cell and Molecular Biology*. 10(4): 384-390.

Hakonarson, H. (2006) Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options. *Current Treatment Options in Cardiovascular Medicine*. 8(3): 183-192.

Hamilton, A.L., Watson, R.M., Wyile, G., O'Byrne, P.M. (1997). Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. *Thorax*. 52(4): 348-354.

Hamelmann, E., Gelfand, E.W. (2001). IL-5-induced airway eosinophilia- the key to asthma? *Annual Review of Immunology*. 179: 182-191.

Hancke, J., Burgos, R., Caceres, D., Wikman, G. (1995). A double-blind study with a new monodrug Kan Jang: decrease of symptoms and improvement in the recovery from common colds. *Phytotherapy Research*. 9: 559-562.

Handa, S.S. (1998). Indian Herbal Pharmacopoeia, Vol. 1. IDMA, Mumbai.

Hansbro, P.M., Kaiko, G.E., Foster, P.S. (2011). Cytokine/anti-cytokine therapy - novel treatments for asthma? *British Journal of Pharmacology*. 163(1): 81-95.

Hansbro, P.M., Scott, G.V., Essilfie, A.T., Kim, R.Y., Starkey, M.R., Nguyen, D.H., Allen, P.D., Kaiko, G.E., Yang, M., Horvat, J.C., Foster, P.S. (2013). Th2 cytokine antagonists: potential treatments for severe asthma. *Expert Opinion on Drug Delivery*. 22(1): 49-69.

Hart, L.A., Krishnan, V.L., Adcock, I.M., Barnes, P.J., Chung, K.F. (1998). Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. *American Journal of Respiratory and Critical Care Medicine*. 158(5):1585-1592.

Hayashi, N., Yoshimoto, T., Izuhara, K., Matsui, K., Tanaka, T., and Nakanishi, K. (2007). T helper 1 cells stimulated with ovalbumin an IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN- $\gamma$  and IL-13 production. *Proceedings of the National Academy of Sciences*. 104: 14765-14770.

He, X., Li, J., Gao, H., Qiu, F., Hu, K., Cui, X., Yao, X. (2003). Identification of a rare sulfonic acid metabolite of andrographolide in rats. *Drug Metabolism and Disposition*. 31(8): 983-985.

Hein, H., Schlüter, C., Kulke, R., Christophers, E., Schröder, J.M., Bartels, J. (1997). Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene. *Biochemical and Biophysical Research Communications*. 237(3): 537-542.

Held, T.K., Weihua, X., Yuan, L., Kalvakolanu, D.V., Cross, A.S. (1999). Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. *Infection and Immunity*. 67(1): 206-212.

Henderson, W.R. Jr, Lewis, D.B., Albert, R.K., Zhang, Y., Lamm, W.J., Chiang, G.K., Jones, F., Eriksen, P., Tien, Y.T., Jonas, M., Chi, E.Y. (1996). The importance of leukotrienes in airway inflammation in a mouse model of asthma. *Journal of Experimental Medicine*. 184(4): 1483-1494.

Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., Scheidereit, C. (2002). Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. *Journal of Experimental Medicine*. 196(5): 605-617.

Hisada, T., Salmon, M., Nasuhara, Y., Chung, K.F. (1999). Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. *American Journal of Respiratory and Critical Care Medicine*. 160(2): 571-575.

Ho, W.E., Cheng, C., Peh, H.Y., Xu, F., Tannenbaum, S.R., Ong, C.N., Wong, W.S. (2012). Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma. *Free Radical Biology and Medicine*. 53(3): 498-507.

Hogan, S.P., Rosenberg, H.F., Moqbel, R., Phipps, S., Foster, P.S., Lacy, P., Kay, A.B., Rothenberg ME. (2008). Eosinophils: biological properties and role in health and disease. *Clinical and Experimental Allergy*. 38(5): 709-750.

Holgate, S.T., Bodey, K.S., Janezic, A., Frew, A.J., Kaplan, A.P., Teran, L.M. (1997). Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. *American Journal of Respiratory and Critical Care Medicine*. 156(5): 1377-1383.

Holgate, S.T., Peters-Golden, M., Panettieri, R.A., Henderson, W.R. Jr. (2003). Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. *Journal of Allergy and Clinical Immunology*. 111(1): S18-34.

Holgate, S.T., Polosa, R. (2008). Treatment strategies for allergy and asthma. *Nature Reviews Immunology*. 8: 218-230.

Holgate, S.T. (2009). Novel targets of therapy in asthma. *Current Opinion in Pulmonary Medicine*. 15(1): 63-71.

Homer, J.J. (2001). A modification to aid open tracheostomy. *Journal of the Royal College of Surgeons of Edinburgh*. 46(3): 189.

Hope, W.C., Welton, A.F., Fiedler-Nagy, C., Batula-Bernardo, C., Coffey, J.W. (1983). In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin. *Biochemical Pharmacology*. 32(2): 367-371.



Hsu, J.H., Liou, S.S., Yu, B.C., Cheng, J.T., Wu, Y.C. (2004). Activation of alpha1A-adrenoceptor by andrographolide to increase glucose uptake in cultured myoblast C2C12 cells. *Planta Medica*. 70(12): 1230-1233.

Hsu, C.H., Hu, C.M., Lu, K.H., Yang, S.F., Tsai, C.H., Ko, C.L., Sun, H.L., Lue, K.H. (2012). Effect of selective cysteinyl leukotriene receptor antagonists on airway inflammation and matrix metalloproteinase expression in a mouse asthma model. *Pediatrics and Neonatology*. 53(4): 235-244.

Huang, T.J., MacArt, P.A., Eynott, P. (2001). Allergen-specific Th1 cells counteract efferent Th2 cell-dependeng bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN- $\gamma$ . *Journal of Immunology*. 166(1): 207-217.

Hudson, C.A., Christophi, G.P., Gruber, R.C., Wilmore, J.R., Lawrence, D.A., Massa, P.T. (2008). Induction of IL-33 expression and activity in central nervous system glia. *Journal of Leukocyte Biology*. 84(3): 631-643.

Hughes, J.E., Srinivasan, S., Lynch, K.R., Proia, R.L., Ferdek, P., Hedrick, C.C. (2008). Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. *Circulation Research*. 102(8): 950-958.

Hughes, M., Inglese, J., Kurtz, A., Andalibi, A., Patton, L., Austin, C., Baltezor, M., Beckloff, M., Sittampalam, S., Weingarten, M., Weir, S. (2012). Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies, <http://www.ncbi.nlm.nih.gov/books/NBK92015>, Assay Guidance Manual.

Huh, J.C., Strickland, D.H., Jahnsen, F.L., Turner, D.J., Thomas, J.A., Napoli, S., Tobagus, I., Stumbles, P.A., Sly, P.D., Holt, P.G. (2003). Bidirectional interactions between antigen-bearing respiratory tract dendritic cells (DCs) and T cells precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. *Journal of Experimental Medicine*. 198(1): 19-30.

Hussain, S.P., He, P., Subleski, J., Hofseth, L.J., Trivers, G.E., Mechanic, L., Hofseth, A.B., Bernard, M., Schwank, J., Nguyen, G., Mathe, E., Djurickovic, D., Haines, D., Weiss, J., Back, T., Gruys, E., Laubach, V.E., Wiltrout, R.H., Harris, C.C. (2008). Nitric oxide is a key component in inflammation-accelerated tumorigenesis. *Cancer Research*. 68: 7130-7136.

Ishikado, A., Nishio, Y., Yamane, K., Mukose, A., Morino, K., Murakami, Y., Sekine, O., Makino, T., Maegawa, H., Kashiwagi, A. (2009). Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells. *Atherosclerosis*; 205(2): 404-412.

Israel, A. (2010). The IKK complex, a central regulator of NF-kappaB activation. *Cold Spring Harbor Perspectives in Biology*. 2(3):a000158.

Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P.J., Adcock, I.M. (2006). Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF- $\kappa$ B suppression. *Journal of Experimental Medicine*. 203: 7-13.

Jacoby, D.B., Gleich, G.J., Fryer, A.D. (1993). Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. *Journal of Clinical Investigation*. 91(4): 1314-1318.

Jada, S.R., Hamzah, A.S., Lajis, N.H., Saad, M.S., Stevens, M.F.G., Stanslas, J. (2006). Semisynthesis and cytotoxic activities of andrographolide analogues. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 21: 145-155.

Jada, S.R., Subur, G.S., Matthews, C., Hamzah, A.S., Lajis, N.H., Saad, M.S., Stevens, M.F., Stanslas, J. (2007). Semisynthesis and in vitro anticancer activities of andrographolide analogues. *Phytochemistry*. 68: 904-912.

Jada, S.R., Matthews, C., Saad, M.S., Hamzah, A.S., Lajis, N.H., Stevens, M.F., Stanslas, J. (2008). Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G1 arrest and apoptosis. *British Journal of Pharmacology*. 155: 641-654.

Jandus, P., Hausmann, O., Haeberli, G., Gentinetta, T., Mueller, U., Helbling, A. (2011). Unpredicted adverse reaction to omalizumab. *Journal of Investigational Allergology and Clinical Immunology*. 21(7): 563-566.

Jang, G.R., Harris, R.Z., Lau, D.T. (2001). Pharmacokinetics and its role in small molecule drug discovery research. *Medicinal Research Review* 21(5): 382-396.

Jarukamjorn, K., Nemoto, N. (2008). Pharmacological aspects of *Andrographis paniculata* on health and its major diterpenoid constituent andrographolide. *Journal of Health Science*. 54: 370-381.

Jeong, Y.J., Kim, K.I., Seo, I.J., Lee, C.H., Lee, K.N., Kim, K.N., Kim, J.S., Kwon, W.J. (2007). Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. *Radiographics*. 27(3): 617-637.

Jiang, D.P., Kolosov, V.P., Perelman, J.M., Zhou, X.D. (2011). Molecular mechanism of interleukin-13-induced mucus hypersecretion in rat airway. *Nan Fang Yi Ke Da Xue Xue Bao*. 31(1): 73-76.

Jiang, Y., Borrelli, L.A., Kanaoka, Y., Bacskai, B.J., Boyce, J.A. (2007). CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. *Blood*. 110(9): 3263-3270.

Jiang, X., Yu, P., Jiang, J., Zhang, Z., Wang, Z., Yang, Z., Tian, Z., Wright, S.C., Larrick, J.W., Wang, Y. (2009). Synthesis and evaluation of antibacterial activities of andrographolide analogues. *European Journal of Medicinal Chemistry*. 44: 2936-2943.

Jones, E., Adcock, I.M., Ahmed, B.Y., Punchard, N.A. (2007). Modulation of LPS stimulated NF-kappaB mediated Nitric Oxide production by PKCepsilon and JAK2 in RAW macrophages. *Journal of Inflammation (London, England)*. 4: 23.

Johnson, J.R., Wiley, R.E., Fattouh, R., Swirski, F.K., Gajewska, B.U., Coyle, A.J., Gutierrez-Ramos, J.C., Ellis, R., Inman, M.D., Jordana, M. (2004). Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. *American Journal of Respiratory and Critical Care Medicine*. 169(3): 378-385.

Justice, J.P., Crosby, J., Borchers, M.T., Tomkinson, A., Lee, J.J., Lee, N.A. (2002). CD4(+) T cell-dependent airway mucus production occurs in response to IL-5 expression in lung. *American Journal of Physiology- Lung Cellular and Molecular Physiology*. 282(5): 1066-1074.

Jutel, M., Pichler, W.J., Skrbic, D., Urwyler, A., Dahinden, C., Müller, U.R. (1995). Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. *Journal of Immunology*. 154(8): 4187-4194.

Juvet, S.C., Han, M., Vanama, R., Joe, B., Kim, E.Y., Zhao, F.L., Jeon, C., Adeyi, O., Zhang, L. (2012). Autocrine IFN $\gamma$  controls the regulatory function of lymphoproliferative double negative T cells. *PLoS One*. 7(10): e47732.

Kaiko, G.E., Horvat, J.C., Beagley, K.W., Hansbro, P.M. (2008). Immunological decision-making: how does the immune system decide to mount a helper T-cell response? *Immunology*. 123(3): 326-338.

Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., Kasuga, M. (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *Journal of Clinical Investigation*. 116(6): 1494-1505.

Kang, H.B., Kim, Y.E., Kwon, H.J., Sok, D.E., Lee, Y. (2007). Enhancement of NF-kappaB expression and activity upon differentiation of human embryonic stem cell line SNUhES3. *Stem Cells and Development*. 16(4): 615-623.

Kariyawasam, H.H., Aizen, M., Barkans, J., Robinson, D.S., Kay, A.B. (2007). Remodeling and airway hyperresponsiveness but not cellular inflammation persists after allergen challenge in asthma. *American Journal of Respiratory and Critical Care Medicine*. 175(9): 896-904.

Katsanos, G.S., Anogeianaki, A., Orso, C., Tetè, S., Salini, V., Antinolfi, P.L., Sabatino, G. (2008). Mast cells and chemokines. *Journal of Biological Regulators & Homeostatic Agents*. 22(3):145-151.



Kawada, M., Hachiya, Y., Arihiro, A., Mizoguchi, E. (2007). Role of mammalian chitinases in inflammatory conditions. *Keio Journal of Medicine*. 56(1): 21-27.

Kawano, T., Matsuse, H., Kondo, Y., Machida, I., Saeki, S., Tomari, S., Mitsuta, K., Obase, Y., Fukushima, C., Shimoda, T., Kohno, S. (2003). Cysteinyl leukotrienes induce nuclear factor kappa b activation and RANTES production in a murine model of asthma. *Journal of Allergy and Clinical Immunology*. 112(2): 369-374.

Kay, A.B. (1992). "Helper" (CD4+) T cells and eosinophils in allergy and asthma. *American Review of Respiratory Disease*. 145(2): S22-S26.

Kazani, S., Sadeh, J., Bunga, S., Wechsler, M.E., Israel, E. (2011). Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. *Respiratory Medicine*. 105(5): 667-673.

Kelly, E.A., Busse, W.W. (2004). Who is captain of the inflammatory ship in asthma? *American Journal of Respiratory and Critical Care Medicine*. 169(5): 551-552.

Kelly, M., Hwang, J.M., Kubes, P. (2007). Modulating leukocyte recruitment in inflammation. *Journal of Allergy and Clinical Immunology*. 120(1): 3-10.

Kennedy, T. (1997). Managing the drug discovery/development interface. *Drug Discovery Today*. 2(10): 436-444.

Keslacy, S., Tliba, O., Baidouri, H., Amrani, Y. (2007). Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. *Molecular Pharmacology*. 71(2): 609-618.

Kidd, P. (2003). Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. *Alternative Medicine Review*. 8(3): 223-246.

Kidney, J., Dominguez, M., Taylor, P.M., Rose, M., Chung, K.F., Barnes, P.J. (1995). Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. *American Journal of Respiratory and Critical Care Medicine*. 151: 1907-1914.

Kim, H.Y., DeKruyff, R.H., Umetsu, D.T. (2010). The many paths to asthma: phenotype shaped by innate and adaptive immunity. *Nat Immunol*. 11(7): 577-584.

Klemm, S., Ruland, J. (2006). Inflammatory signal transduction from FcεRI to NF-κB. *Immunobiology*. 211: 815-820.

Knox, A.J., Mortimer, K. (2008). Combining inhaled glucocorticoids and long acting beta (2)-adrenoceptor agonists in asthma and COPD. *British Journal of Pharmacology*. 153(6):1085-1086.

Koh, Y.Y., Dupuis, R., Pollice, M., Albertine, K.H., Fish, J.E., Peters, S.P. (1993). Neutrophils recruited to the lungs of humans by segmental antigen challenge display a reduced chemotactic response to leukotriene B<sub>4</sub>. *American Journal Respiratory Cell and Molecular Biology*. 8(5): 493-499.

Kong, L.R. (2009). *Anti-inflammatory Effects of 14-deoxy-11,12-didehydroandrographolide in a Mouse Asthma Model*. Unpublished Bachelor of Science dissertation, National University of Singapore, Singapore.

Korhonen, R., Lahti, A., Kankaanranta, H., Moilanen, E. (2005). Nitric oxide production and signaling in inflammation. *Current Drug Targets- Inflammation and Allergy*. 4(4):471-479.

Kraft, M., Adler, K.B., Ingram, J.L., Crews, A.L., Atkinson, T.P., Cairns, C.B., Krause, D.C., Chu, H.W. (2008). Mycoplasma pneumoniae induces airway epithelial cell expression of MUC5AC in asthma. *European Respiratory Journal*. 31(1):43-46.

Kraneveld, A.D., Folkerts, G., Van Oosterhout, A.J., Nijkamp, F.P. (1997). Airway hyperresponsiveness: first eosinophils and then neuropeptides. *International Journal of Immunopharmacology*. 19(9-10): 517-527.

Kroegel, C., Bergmann, N., Foerster, M., Workalemahu, G., Machnik, A., Mock, B., Reissig, A. (2006). Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. *Respiration*. 73(4): 566-570.

Kumar, A., Takada, Y., Boriek, A.M., Aggarwal, B.B. (2004). Nuclear factor-kappaB: its role in health and disease. *Journal of Molecular Medicine*. 82(7): 434-448.

Kumar, R.K., Herbert, C., Foster, P.S. (2008). The "classical" ovalbumin challenge model of asthma in mice. *Current Drug Targets*. 9(6): 485-494.

Kumasawa, F., Hashimoto, S., Mizumura, K., Takeshita, I., Onose, A., Jibiki, I., Maruoka, S., Gon, Y., Kobayashi, T., Takahashi, N. (2013). Mitogen-activated protein kinase (MAPK) regulates leukotriene D<sub>4</sub>-induced HB-EGF and ADAM12 expression in human airway smooth muscle cells. *Asian Pacific Journal of Allergy and Immunology*. 31(1): 58-66.

Kunsch, C., Rosen, C.A. (1993). NF-kappa B subunit-specific regulation of the interleukin-8 promoter. *Molecular and Cellular Biology*. 13(10): 6137-6146.

Kurokawa, M., Matsukura, S., Kawaguchi, M., Ieki, K., Suzuki, S., Watanabe, S., Homma, T., Yamaguchi, M., Takeuchi, H., Adachi, M. (2013). Interleukin-33-activated dendritic cells induce the production of thymus and activation-regulated chemokine and macrophage-derived chemokine. *International Archives of Allergy and Immunology*. 161(2): 52-57.

Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R.C., Stolarski, B., Garcia, C.C., Komai-Koma, M., Pitman, N., Li, Y., Niedbala, W., McKenzie, A.N., Teixeira, M.M., Liew, F.Y., Xu, D. (2008). IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. *Journal of Immunology*. 181(7): 4780-4790.

Laidlaw, T.M., Boyce, J.A. (2012). Cysteinyl leukotriene receptors, old and new; implications for asthma. *Clinical and Experimental Allergy*. 42(9): 1313-1320.

Lassalle, P., Gosset, P., Delneste, Y., Tscopoulos, A., Capron, A., Joseph, M., Tonnel, A.B. (1993). Modulation of adhesion molecule expression on endothelial cells during the late asthmatic reaction: role of macrophage-derived tumour necrosis factor-alpha. *Clinical and Experimental Immunology*. 94(1): 105-110.

Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., Willoughby, D.A. (2001). Possible new role for NF-kappaB in the resolution of inflammation. *Nature Medicine*. 7(12): 1291-1297.

Lee, K.H., Chow, Y.L., Sharmili, V., Abas, F., Alitheen, N.B., Shaari, K., Israf, D.A., Lajis, N.H., Syahida, A. (2012). BDMC33, A Curcumin Derivative Suppresses Inflammatory Responses in Macrophage-Like Cellular System: Role of Inhibition in NF- $\kappa$ B and MAPK Signaling Pathways. *International Journal of Molecular Science*. 13(3): 2985-3008.

Leeson, P. (2012). Drug discovery: Chemical beauty contest. *Nature*. 481: 455-456

Leigh, R., Ellis, R., Wattie, J., Donaldson, D.D., Inman, M.D. (2004). Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? *American Journal of Respiratory and Critical Care Medicine*. 170(8): 851-856.

Lemanske, R.F. Jr., Busse, W.W. (2006). 6. Asthma: Factors underlying inception, exacerbation, and disease progression. *Journal of Allergy and Clinical Immunology*. 117(2): S456-461.

Levine, S.J., Wenzel, S.E. (2011). Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. *Annals of Internal Medicine*. 152(4): 232-237.

Leynaert, B., Neukirch, C., Liard, R., Bousquet, J., Neukirch, F. (2000). Quality of life in allergic rhinitis and asthma. A population-based study of young adults. *American Journal of Respiratory and Critical Care Medicine*. 162(4): 1391-1396.

Li, C., Liu, B., Chang, J., Groessl, T., Zimmerman, M., He, Y.Q., Isbell, J., Tuntland, T. (2013). A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery. *Drug Discovery Today*. 18(1-2): 71-78.

Li, L., Xia, Y., Nguyen, A., Lai, Y.H., Feng, L., Mosmann, T.R., Lo, D. (1999). Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. *Journal of Immunology*. 162(5): 2477-2487.

Li, J., Huang, W., Zhang, H., Wang, X., Zhou, H. (2007). Synthesis of andrographolide derivatives and their TNF- $\alpha$  and IL-6 expression inhibitory activities. *Bioorganic and Medicinal Chemistry Letters*. 17: 6891-6894.

Li, Y.J., Yu, C.H., Li, J.B., Wu, X.Y. (2013). Andrographolide antagonizes cigarette smoke extract-induced inflammatory response and oxidative stress in human alveolar epithelial A549 cells through induction of microRNA-218. *Experimental Lung Research*. 39(10): 463-471.

Lim, S.H. (2007). *Mechanisms of Antitumor Activity of 3,19-(2-Bromobenzylidene) Andrographolide*. Unpublished master dissertation, Universiti Putra Malaysia, Malaysia.

Lim, J.C., Chan, T.K., Ng, D.S., Sagineedu, S.R., Stanslas, J., Wong, W.S. (2012). Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. *Clinical and Experimental Pharmacology and Physiology*. 39(3): 300-310.

Lin, J.H., Lu, A.Y. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. *Pharmacological Review*. 49(4): 403-449.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 46(1-3): 3-26.

Liu, M.C., Hubbard, W.C., Proud, D., Stealey, B.A., Galli, S.J., Kagey-Sobotka, A., Bleecker, E.R., Lichtenstein, L.M. (1991). Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. *American Review of Respiratory Disease*. 144(1): 51-58.

Liu, S.F., Haddad, E.B., Adcock, I., Salmon, M., Koto, H., Gilbey, T., Barnes, P.J., Chung, K.F. (1997). Inducible nitric oxide synthase after sensitisation and allergen challenge of Brown Norway rat lung. *British Journal of Pharmacology*. 121(7): 1241-1246.

Li-Weber, M., Krammer, P.H. (2003). Regulation of IL4 gene expression by T cells and therapeutic perspectives. *Nature Review Immunology*. 3(7): 534-543.

Loh, L.C., Wong, P.S. (2005). Asthma prescribing practices of government and private doctors in Malaysia--a nationwide questionnaire survey. *Asian Pacific journal of Allergy and Immunology*. 23(1): 7-17.



Long, A.A. (2009). Monoclonal antibodies and other biologic agents in the treatment of asthma. *MAbs*. 1(3): 237-246.

Lopez, A.F., Sanderson, C.J., Gamble, J.R., Campbell, H.D., Young, I.G., Vadas, M.A. (1988). Recombinant human interleukin 5 is a selective activator of human eosinophil function. *Journal of Experimental Medicine*. 167(1): 219-224.

Lora, J.M., Zhang, D.M., Liao, S.M., Burwell, T., King, A.M., Barker, P.A., Singh, L., Keaveney, M., Morgenstern, J., Gutiérrez-Ramos, J.C., Coyle, A.J., Fraser, C.C. (2005). Tumor necrosis factor- $\alpha$  triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism. *Journal of Biological Chemistry*. 280(43): 36510-36517.

Louis, R., Schleich, F., Barnes, P.J. (2012). Corticosteroids: still at the frontline in asthma treatment? *Clinics in Chest Medicine*. 33(3): 531-541.

Lu, S., Liu, N., Dass, S.B., Reiss, T.F. (2009). A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. *Journal of Asthma*. 46(5): 465-469.

Lu, W.J., Lee, J.J., Chou, D.S., Jayakumar, T., Fong, T.H., Hsiao, G., Sheu, J.R. (2011). A novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet activation: the pivotal mechanisms of endothelial nitric oxide synthase/cyclic GMP. *Journal of Molecular Medicine*. 89(12):1261-1273.

Luster, M.I., Simeonova, P.P. (1998). Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factors. *Toxicology Letters*. 102-103: 271-275.

MacMicking, J., Xie, Q.W., Nathan, C. (1997). Nitric oxide and macrophage function. *Annual Review of Immunology*. 5: 323-350.

Mahmood, I., Balian, J.D. (1999). The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. *Clinical Pharmacokinetics*. 36(1): 1-11.

Maimaiti, G., Abduhaer, A., Xu, P.R. (2011). Evaluation of efficacy and safety of loratadine in the treatment of childhood asthma. *Zhongguo Dang Dai Er Ke Za Zhi*. 13(11): 873-877.

Mak, J.C., Chan-Yeung, M.M. (2006). Reactive oxidant species in asthma. *Current Opinion in Pulmonary Medicine*. 12(1): 7-11.

Malm-Erjefält, M., Greiff, L., Ankerst, J., Andersson, M., Wallengren, J., Cardell, L.O., Rak, S., Persson, C.G., Erjefält, J.S. (2005). Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. *Clinical and Experimental Allergy*. 35(10): 1334-1340.

Malomo, S.O. (2000). Toxicological implication of ceftriaxone administration in rats. *Nigerian Society of Biochemistry and Molecular Biology*. 15(1): 33-38.

Maneechotesuwan, K., Xin, Y., Ito, K., Jazrawi, E., Lee, K.Y., Usmani, O.S., Barnes, P.J., Adcock, I.M. (2007). Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. *Journal of Immunology*. 178(4): 2491-2498.

Masoli, M., Fabian, D., Holt, S., Beasley, R., Global Initiative for Asthma (GINA) Program. (2004). The global burden of asthma: executive summary of the GINA Dissemination Committee Report. *Allergy*. 59(5): 469-478.

Matsumoto, A., Hiramatsu, K., Li, Y., Azuma, A., Kudoh, S., Takizawa, H., Sugawara, I. (2006). Repeated exposure to low-dose diesel exhaust after allergen challenge exaggerates asthmatic responses in mice. *Clinical Immunology*. 121(2): 227-235.

Markman M. (2004). Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer. *Journal of Clinical Oncology*. 22(8): 1527-1529.

McCarthy, M.K., Weinberg, J.B. (2012). Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. *Mediators of Inflammation*. 2012: 236345.

McKay, L.I., Cidowski, J.A. (1998). Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. *Molecular Endocrinology*. 12(1): 45-56.

Meanwell, N.A. (2011). Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. *Chemical Research in Toxicology*. 24(9): 1420-1456.

Medoff, B.D., Thomas, S.Y., Luster, A.D. (2008). T cell trafficking in allergic asthma: the ins and outs. *Annual Review of Immunology*. 26: 205-232.

Meerschaert, J., Kelly, E.A., Mosher, D.F., Busse, W.W., Jarjour, N.N. (1999). Segmental antigen challenge increases fibronectin in bronchoalveolar lavage fluid. *American Journal of Respiratory and Critical Care Medicine*. 159(2): 619-625.

Melchior, J., Palm, S., Wikman, G. (1997). Controlled clinical study of standardized *Andrographis paniculata* extract in common cold - a pilot trial. *Phytomedicine*. 3(4): 315-318.

Mocatta, T.J., Pilbrow, A.P., Cameron, V.A., Senthilmohan, R., Frampton, C.M., Richards, A.M., Winterbourn, C.C. (2007). Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. *Journal of the American College of Cardiology*. 49: 1993-2000.

Moffatt, M.F., Cookson, W.O. (2008). Asthma and chitinases. *New England Journal of Medicine*. 358(16): 1725-1726.

Moote, W., Kim, H. (2011). Allergen-specific immunotherapy. *Allergy, Asthma and Clinical Immunology*. 7(1): S5.

Moriuchi, H., Moriuchi, M., Fauci, A.S. (1997). Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. *Journal of Immunology*. 158(7): 3483-3491.

Munakata, M. (2006). Airway remodeling and airway smooth muscle in asthma. *Allergy International*. 55(3): 235-243.

Murphy, R.C., Gijon, M.A. (2007). Biosynthesis and metabolism of leukotrienes. *Biochemical Journal*. 405(3): 379-395.

Murray, J.J., Tonnel, A.B., Brash, A.R., Roberts, L.J. 2nd, Gosset, P., Workman, R., Capron, A., Oates, J.A. (1985). Prostaglandin D<sub>2</sub> is released during acute allergic bronchospasm in man. *Transactions of the Association of American Physicians*. 98: 275-280.

Montefort, S., Gratziau, C., Goulding, D., Polosa, R., Haskard, D.O., Howarth, P. H., Holgate, S.T., Carroll, M.P. (1994). Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. *Journal of Clinical Investigation*. 93(4): 1411-1421.

Morcillo, E.J., Cortijo, J. (2006). Mucus and MUC in asthma. *Current Opinion in Pulmonary Medicine*. 12(1): 1-6.

Moriuchi, H., Moriuchi, M., Fauci, A.S. (1997). Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. *Journal of Immunology*. 158(7): 3483-3491.

Mullan, C.S., Riley, M., Clarke, D., Tatler, A., Sutcliffe, A., Knox, A.J., Pang, L. (2008). Beta-tryptase regulates IL-8 expression in airway smooth muscle cells by a PAR-2-independent mechanism. *American Journal of Respiratory Cell and Molecular Biology*. 38(5): 600-608.

Myou, S., Leff, A.R., Myo, S., Boetticher, E., Tong, J., Meliton, A.Y., Liu, J., Munoz, N.M., Zhu, X. (2003). Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. *Journal of Experimental Medicine*. 198(10): 1573-1582.

Nadchatram, M. (2005). House dust mites, our intimate associates. *Tropical Biomedicine*. 22(1): 23-37.



Nadeem, A., Raj, H.G., Chhabra, S.K. (2005). Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. *Inflammation*. 29(1): 23-32.

Nadeem, A., Masood, A., Siddiqui, N. (2008). Oxidant--antioxidant imbalance in asthma: scientific evidence, epidemiological data and possible therapeutic options. *Therapeutic Advances in Respiratory Disease*. 2(4): 215-235.

Naik, S.R., Hule, A. (2009). Evaluation of immunomodulatory activity of an extract of andrographolides from *Andrographis paniculata*. *Planta Medica*. 75(8):785-791.

Nakanishi, C., Toi, M. (2005). Nuclear factor- $\kappa$ B inhibitors as sensitizers to anticancer drugs. *Nature Review Cancer*. 5: 297-309.

Nanduri, S., Nyavanandi, V.K., Thunuguntla, S.S., Kasu, S., Pallerla, M.K., Ram, P.S., Rajagopal, S., Kumar, R.A., Ramanujam, R., Babu, J.M., Vyas, K., Devi, A.S., Reddy, G.O., Akella, V. (2004). Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents. *Bioorganic & Medicinal Chemistry Letters*. 14: 4711-4717.

Natoli, G. (2009). Control of NF-kappaB-dependent transcriptional responses by chromatin organization. *Cold Spring Harbor Perspectives in Biology*. 1(4): a000224.

Nelson, H.S. (2001). Future advances of immunotherapy. *Allergy and Asthma Proceedings*. 22(4): 203-207.

Nelson, H.S. (2005). Advances in upper airway diseases and allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 115(4): 676-684.

Nemec, A., Pavlica, Z., Petelin, M., Crossley, D.A., Sentjurc, M., Jerin, A., Erzen, D., Zdovc, I., Hitti, T., Skaleric, U. (2010). Systemic use of selective iNOS inhibitor 1400W or non-selective NOS inhibitor l-NAME differently affects systemic nitric oxide formation after oral *Porphyromonas gingivalis* inoculation in mice. *Archives of Oral Biology*. 55(7): 509-514.

Neveu, W.A., Allard, J.L., Raymond, D.M., Bourassa, L.M., Burns, S.M., Bunn, J.Y., Irvin, C.G., Kaminsky, D.A., Rincon, M. (2010). Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. *Respiratory Research*. 11: 28.

Newton, R., Holden, N.S., Catley, M.C., Dyelusi, W., Leigh, R., Proud, D., Barnes, P.J. (2007). Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule I $\kappa$ B kinase inhibitors. *Journal of Pharmacology and Experimental Therapeutics*. 321: 734-742.

Ngui, R., Lim, Y.A.L., Chow, S.C., De Bruyne, J.A., Liam, C.K. (2011). Prevalence of Bronchial Asthma among Orang Asli in Peninsular Malaysia. *Medical Journal of Malaysia*. 66(1): 27-31.

Nials, A.T., Uddin, S. (2008). Mouse models of allergic asthma: acute and chronic allergen challenge. *Disease Model and Mechanism*. 1(4-5): 213-220.

Nisar, A., Malik, A.H., Zargar, M.A. (2013). Atropa acuminata blunts production of pro-inflammatory mediators eicosanoids., leukotrienes, cytokines in vitro and in vivo models of acute inflammatory responses. *Journal of Ethnopharmacology*. 147(3): 584-594.

Nocker, R.E., Schoonbrood, D.F., van de Graaf, E.A., Hack, C.E., Lutter, R., Jansen, H.M., Out, T.A. (1996). Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. *International Archives of Allergy and Immunology*. 109(2): 183-191.

Novak, N., Bieber, T. (2003). Allergic and nonallergic forms of atopic diseases. *Journal of Allergy and Clinical Immunology*. 112(2): 252-62.

O'Byrne, P.M., Inman, M.D. (2003). Airway hyperresponsiveness. *Chest*. 123(3): 411S-416S.

O'Connor, S., Shumway, S.D., Amanna, I.J., Hayes, C.E., Miyamoto, S. (2004). Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells. *Molecular and Cell Biology*. 24(11): 4895-4908.

Oro, A.S., Guarino, T.J., Driver, R., Steinman, L., Umetsu, D.T. (1996). Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. *Journal of Allergy and Clinical Immunology*. 97(6): 1402-1408.

Parmentier, C.N., Fuerst, E., McDonald, J., Bowen, H., Lee, T.H., Pease, J.E., Woszczek, G., Cousins, D.J. (2012). Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. *Journal of Allergy and Clinical Immunology*. 129(4): 1136-1142.

Panettieri, R.A., Tan, E.M., Ciocca, V., Luttmann, M.A., Leonard, T.B., Hay, D.W. (1998). Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction *In vitro*: differential sensitivity to cysteinyl leukotriene receptor antagonists. *American Journal of Respiratory Cell and Molecular Biology*. 19(3): 453-461.

Paton, J.Y. (2013). Republished: Perception of lung function, adherence to inhaled corticosteroids, and the role of peak expiratory flow feedback in paediatric asthma. *Postgraduate Medical Journal*. 89(1048): 61-62.

Pearson, R.M. (1986). In-vitro techniques: can they replace animal testing? *Human Reproduction*. 1(8): 559-560.

Pelkonen, O., Turpeinen, M., Raunio, H. (2011). In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. *Clinical Pharmacokinetics*. 50(8): 483-491.

Peng, Z., Liu, Q., Wang, Q., Rector, E., Ma, Y., Warrington, R. (2007). Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. *Clinical and Experimental Allergy*. 37(7): 1040-1048.

Perkins, C., Wills-Karp, M., Finkelman, F.D. (2006). IL-4 induces IL-13-independent allergic airway inflammation. *Journal of Allergy and Clinical Immunology*. 118(2): 410-419.

Persson, C.G., Andersson, M., Greiff, L., Svensson, C., Erjefält, J.S., Sundler, F., Wollmer, P., Alkner, U., Erjefält, I., Gustafsson, B., Linden, M., Nilsson, M. (1995). Airway permeability. *Clinical and Experimental Allergy*. 25(9): 807-814.

Peters-Golden, M. (2004). The alveolar macrophage: the forgotten cell in asthma. *American Journal of Respiratory Cell and Molecular Biology*. 31(1): 3-7.

Peters, S.P., Ferguson, G., Deniz, Y., Reisner, C. (2006). Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. *Respiratory Medicine*. 100: 1139-1151.

Phillips, R.M., Jaffar, M., Maitland, D.J., Loadman, P.M., Shnyder, S.D., Steans, G., Cooper, P.A., Race, A., Patterson, A.V., Stratford, I.J. (2004). Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. *Biochemical Pharmacology*. 68(11): 2107-2116.

Pholphana, N., Rangkadilok, N., Thongnest, S., Ruchirawat, S., Ruchirawat, M., Satayavivad, J. (2004). Determination and variation of three active diterpenoids in *Andrographis paniculata* (Burm.f.) Nees. *Phytochemical Analysis*. 15(6): 365-371.

Platts-Mills, T.A. (2001). The role of immunoglobulin E in allergy and asthma. *American Journal of Respiratory and Critical Care Medicine*. 164(8): S1-S5.

Poolsup, N., Suthisisang, C., Prathanturarug, S., Asawamekin, A., Chanchareon, U. (2004). *Andrographis paniculata* in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. *Journal of Clinical Pharmacy and Therapeutics*. 29(1): 37-45.

Portnoy, J.M., Dinakar, C. (2004). Review of cetirizine hydrochloride for the treatment of allergic disorders. *Expert Opinion on Pharmacotherapy*. 5(1): 125-135.

Poynter, M.E., Cloots, R., van Woerkom, T., Butnor, K.J., Vacek, P., Taatjes, D.J., Irvin, C.G., Janssen-Heininger, Y.M. (2004). NF-kappa B activation in airways modulates

allergic inflammation but not hyperresponsiveness. *Journal of Immunology*. 173(11): 7003-7009.

Prado, C.M., Leick-Maldonado, E.A., Yano, L., Leme, A.S., Capelozzi, V.L., Martins, M.A., Tibério, I.F. (2006). Effects of nitric oxide synthases in chronic allergic airway inflammation and remodeling. *American Journal of Respiratory Cell and Molecular Biology*. 35(4): 457-465.

Prado, C.M., Yano, L., Rocha, G., Starling, C.M., Capelozzi, V.L., Leick-Maldonado, E.A., Martins Mde, A., Tibério, I.F. (2011). Effects of inducible nitric oxide synthase inhibition in bronchial vascular remodeling-induced by chronic allergic pulmonary inflammation. *Experimental Lung Research*. 37(5): 259-268.

Provost, V., Langlois, A., Chouinard, F., Rola-Pleszczynski, M., Chakir, J., Flamand, N., Laviolette, M. (2012). Leukotriene D4 and interleukin-13 cooperate to increase the release of eotaxin-3 by airway epithelial cells. *PLoS One*. 7(8): e43544.

Pukelsheim, K., Stoeger, T., Kutschke, D., Ganguly, K., Wjst, M. (2010). Cytokine profiles in asthma families depend on age and phenotype. *PLoS One*. 5(12):e14299.

Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. *et al.* (2007). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*. 176: 532-555.

Radulovic, S., Calderon, M.A., Wilson, D., Durham, S. (2010). Sublingual immunotherapy for allergic rhinitis. *Cochrane Database of Systematic Reviews*. 2010(2): CD002893.

Rahman, A., Kefer, J., Bando, M., Niles, W.D., Malik, A.B. (1998). E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappaB activation. *American Journal of Physiology*. 275(3): L533-L544.

Rahman, I., Biswas, S.K., Kode, A. (2006). Oxidant and antioxidant balance in the airways and airway diseases. *European Journal of Pharmacology*. 533(1-3): 222-239.

Renauld, J.C. (2001). New insights into the role of cytokines in asthma. *Journal of Clinical Pathology*. 54(8): 577-589.

Ricciardolo, F.L.M. (2003). Multiple roles of nitric oxide in the airways. *Thorax*. 58(2): 175-182.

Richardson, P.J., Walker, J.H., Jones, R.T., Whittaker, V.P. (1982). Identification of a cholinergic-specific antigen Chol-1 as a ganglioside. *Journal of Neurochemistry*. 38(6): 1605-1614.



Rivington, R.N., Boulet, L.P., Côté, J., Kreisman, H., Small, D.I., Alexander, M., Day, A., Harsanyi, Z., Darke, A.C. (1995). Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. *American Journal of Respiratory and Critical Care Medicine*. 151: 325-332.

Roberts, L.J., Fessel, J.P. (2004). The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. *Chemistry and Physics of Lipids*. 128(1-2): 173-186.

Robinson, D.S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham, S.R., Kay, A.B. (1992). Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. *New England Journal of Medicine*. 326: 298-304.

Robinson, D., Hamid, Q., Bentley, A., Ying, S., Kay, A.B., Durham, S.R. (1993). Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. *Journal of Allergy and Clinical Immunology*. 92(2): 313-324.

Robinson, D.S. (2013). Mepolizumab for severe eosinophilic asthma. *Expert Review of Respiratory Medicine*. 7(1): 13-17.

Roquet, A., Dahlén, B., Kumlin, M., Ihre, E., Anstrén, G., Binks, S., Dahlén, S.E. (1997). Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. *American Journal of Respiratory and Critical Care Medicine*. 155(6): 1856-1863.

Rothenberg, M.E., Ownbey, R., Mehlhop, P.D., Loiselle, P.M., van de Rijn, M., Bonventre, J.V., Oettgen, H.C., Leder, P., Luster, A.D. (1996). Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. *Molecular Medicine*. 2(3): 334-348.

Roy, P.K., Rashid, F., Bragg, J., Ibdah, J.A. (2008). Role of the JNK signal transduction pathway in inflammatory bowel disease. *World Journal of Gastroenterology*. 4(2): 200-202.

Rozlan, I. (2002). The study on asthma admissions in Malaysia. Disease Control Division (NCD). *Ministry of Health Malaysia*. 1: 10-17.

Sade, K., Kivity, S. (2002). Nitric oxide in asthma. *Israel Medical Association Journal*. 4(3): 196-199.

Salmon, M., Walsh, D.A., Huang, T.J., Barnes, P.J., Leonard, T.B., Hay, D.W., Chung, K.F. (1999). Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA

synthesis after repeated allergen exposure in sensitized Brown Norway rats. *British Journal of Pharmacology*. 127(5): 1151-1158.

Sanderson, C.J. (1992). Interleukin-5, eosinophils, and disease. *Blood*. 79(12): 3101-3109.

Sarpong, S.B., Zhang, L.Y., Kleeberger, S.R. (2003). A novel mouse model of experimental asthma. *International Archives of Allergy and Immunology*. 132(4): 346-354.

Sasaki, C.Y., Barberi, T.J., Ghosh, P., Longo, D.L. (2005). Phosphorylation of RelA/p65 on serine 536 defines an I $\kappa$ B $\alpha$ -independent NF- $\kappa$ B pathway. *Journal of Biological Chemistry*. 280: 34538-34547.

Sausbier, M., Zhou, X.B., Beier, C., Sausbier, U., Wolpers, D., Maget, S., Martin, C., Dietrich, A., Ressmeyer, A.R., Renz, H., Schlossmann, J., Hofmann, F., Neuhuber, W., Gudermann, T., Uhlig, S., Korth, M., Ruth, P. (2007). Reduced rather than enhanced cholinergic airway constriction in mice with ablation of the large conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel. *FASEB Journal*. 21(3): 812-822.

Satyanarayana, C., Deevi, D., Rajagopalan, R., Srinivas, N., Rajagopal, S. (2004). DRF 3188 a novel semi-synthetic analog of andrographolide: Cellular response to MCF 7 breast cancer cells. *BMC Cancer*. 4: 26.

Scarfì, S., Magnone, M., Ferraris, C., Pozzolini, M., Benvenuto, F., Benatti, U., Giovine, M. (2009). Ascorbic acid pre-treated quartz stimulates TNF-alpha release in RAW 264.7 murine macrophages through ROS production and membrane lipid peroxidation. *Respiratory Research*. 10: 25.

Schacke, H., Hennekes, H., Schottelius, A., Jaroch, S., Lehmann, M., Schmees, N., Rehwinkel, H., Asadullah, K. (2002). SEGRAS: a novel class of anti-inflammatory compounds. *Ernst Schering Foundation Symposium Proceedings*. (40): 357-371.

Schafer, D., Lindenthal, U., Wagner, M., Bolcskei, P.L., Baenkler, H.W. (1996). Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. *Thorax*. 51(9): 919-923.

Shifren, A., Witt, C., Christie, C., Castro, M. (2012). Mechanisms of remodeling in asthmatic airways. *Journal of Allergy (Cairo)*. 2012: 316049.

Shimizu, H., Obase, Y., Katoh, S., Mouri, K., Kobashi, Y., Oka, M. (2013). Critical role of interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model. *Inflammation Research*. 62(10): 911-917.

Schindler, U., Baichwal, V.R. (2004). Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. *Molecular and Cellular Biology*. 14(9): 5820-5831.



Schleich, F.N., Asandei, R., Manise, M., Sele, J., Seidel, L., Louis, R. (2012). Is FENO50 useful diagnostic tool in suspected asthma? *International Journal of Clinical Practice*. 66(2): 158-165.

Schmidt-Weber, C.B. (2012). Anti-IL-4 as a new strategy in allergy. *Chemical Immunology and Allergy*. 96: 120-125.

Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D.M., Bazan, J.F., Kastelein, R.A. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity*. 23(5): 479-490.

Schreck, R., Zorbas, H., Winnacker, E.L., Baeuerle, P.A. (1990). The NF-kappa B transcription factor induces DNA bending which is modulated by its 65-kD subunit. *Nucleic Acids Research*. 18(22): 6497-6502.

Schroder, K., Sweet, M.J., Hume, D.A. (2006). Signal integration between IFN gamma and TLR signaling pathways in macrophages. *Immunobiology*. 211(6-8): 511-524.

Schulze-Luehrmann, J., Ghosh, S. (2006). Antigen-receptor signaling to nuclear factor kappa B. *Immunity*. 25(5): 701-715.

Shaari, K., Suppaiah, V., Wai, L.K., Stanslas, J., Tejo, B.A., Israf, D.A., Abas, F., Ismail, I.S., Shuaib, N.H., Zareen, S., Lajis, N.H. (2011). Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from *Melicope ptelefolia* and molecular insights into its interaction with 5-lipoxygenase. *Bioorganic and Medicinal Chemistry*. 19(21): 6340-6347.

Sheeja, K., Kuttan, G. (2007a). Modulation of natural killer cell activity, antibody-dependent cellular cytotoxicity, and antibody-dependent complement-mediated cytotoxicity by andrographolide in normal and Ehrlich ascites carcinoma-bearing mice. *Integrative Cancer Therapies*. 6(1): 66-73.

Sheeja, K., Kuttan, G. (2007b). Activation of cytotoxic T lymphocyte responses and attenuation of tumor growth in vivo by *Andrographis paniculata* extract and andrographolide. *Immunopharmacology and Immunotoxicology*. 29(1): 81-93.

Shen, F., Hu, Z., Goswami, J., Gaffen, S.L. (2006). Identification of common transcriptional regulatory elements in interleukin-17 target genes. *Journal of Biological Chemistry*. 281(34): 24138-24148.

Shen, K.K., Liu, T.Y., Xu, C., Ji, L.L., Wang, Z.T. (2009). Andrographolide inhibits hepatoma cells growth and affects the expression of cell cycle related proteins. *Yao Xue Xue Bao*. 44: 973-997.

Shen, Y.C., Chen, C.F., Chiou, W.F. (2000). Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide. *Planta Medicine*. 66: 314-317.

Shen, Y.C., Chen, C.F., Chiou, W.F. (2002). Andrographolide prevents oxygen radical production by human neutrophils: Possible mechanism (s) involved in its anti-inflammatory effect. *British Journal of Pharmacology*. 135: 399-406.

Shim, Y.M., Zhu, Z., Zheng, T., Lee, C.G., Homer, R.J., Ma, B., Elias, J.A. (2006). Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. *Journal of Immunology*. 177(3): 1918-1924.

Shirai, T., Sato, A., Chida, K., Hayakawa, H., Akiyama, J., Iwata, M., Taniguchi, M., Reshad, K., Hara, Y. (1997). Epigallocatechin gallate-induced histamine release in patients with green tea-induced asthma. *Annals of Allergy, Asthma and Immunology*. 79(1): 65-69.

Shirakawa, T., Enomoto, T., Shimazu, S., Hopkin, J.M. (1997). The inverse association between tuberculin responses and atopic disorder. *Science*. 275(5296): 77-79.

Shuhui, L., Mok, Y.K., Wong, W.S. (2009). Role of mammalian chitinases in asthma. *International Archives of Allergy and Immunology*. 149(4): 369-377.

Shukla, B., Visen, P.K., Patnaik, G.K., Dhawan, B.N. (1992). Choleric effect of andrographolide in rats and guinea pigs. *Planta Medica*. 58(2): 146-149.

Sibbald, B., Turner-Warwick, M. (1979). Factors influencing the prevalence of asthma among first degree relatives of extrinsic and intrinsic asthmatics. *Thorax*. 34(3): 332-337.

Siddiqui, S., Martin, J.G. (2008). Structural aspects of airway remodeling in asthma. *Current Allergy and Asthma Reports*. 8(6): 540-547.

Silverman, E., In, K.H., Yandava, C., Drazen, J.M. (1998). Pharmacogenetics of the 5-lipoxygenase pathway in asthma. *Clinical and Experimental Allergy*. 28(5): 164-170.

Simon, H.U., Seelbach, H., Ehmann, R., Schmitz, M. (2003). Clinical and immunological effects of low-dose IFN $\alpha$  treatment in patients with corticosteroid-resistant asthma. *Allergy*. 58: 1250-1255.

Singha, P.K., Roy, S., Dey, S. (2007). Protective activity of andrographolide and arabinogalactan proteins from *Andrographis paniculata* Nees. against ethanol-induced toxicity in mice. *Journal of Ethnopharmacology*. 111(1): 13-21.

Singh, N. (2002). Preemptive therapy for cytomegalovirus with oral ganciclovir after liver transplantation. *Transplantation*. 73(12): 1977.

Singh, S.S. (2006). Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. *Current Drug Metabolism*. 7(2): 165-182.

Singh, D., Kane, B., Molino, N.A., Faggioni, R., Roskos, L., Woodcock, A. (2010). A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. *BMC Pulmonary Medicine*. 10: 3.

Siva, S.R.T., Vijay, K.N., Srinivas, N. (2004). A facile route for the synthesis of limonidilactone analogues from andrographolide. *Tetrahedron Letters*. 45: 9357-9360.

Smith, H.R., Larsen, G.L., Cherniack, R.M., Wenzel, S.E., Voelkel, N.F., Westcott, J.Y., Bethel, R.A. (1992). Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness. *Journal of Allergy and Clinical Immunology*. 89:1076-1084.

Soler, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., Della Cioppa, G. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *European Respiratory Journal*. 18: 254–261.

Son, Y.H., Jeong, Y.T., Lee, K.A., Choi, K.H., Kim, S.M., Rhim, B.Y., Kim, K. (2008). Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. *Journal of Cardiovascular Pharmacology*. 51(1): 71-77.

Song, J.S., Kang, C.M., Yoo, M.B., Kim, S.J., Yoon, H.K., Kim, Y.K., Kim, K.H., Moon, H.S., Park, S.H. (2007). Nitric oxide induces MUC5AC mucin in respiratory epithelial cells through PKC and ERK dependent pathways. *Respiratory Research*. 8: 28.

Spangler, D.L. (2012). The role of inhaled corticosteroids in asthma treatment: a health economic perspective. *American Journal of Managed Care*. 18(2): S35-S39.

Sridhar, A.V., McKean, M. (2006). Nedocromil sodium for chronic asthma in children. *Cochrane Database of Systemic Reviews*. (3): CD004108.

Stanslas, J., Liew, P.S., Lftlkhar, N., Lee, C.P., Saad, S., Lajis, N., Robins, R.A., Loadman, P., Bibby, M.C. (2001). Potential of AG in the treatment of breast cancer. *European Journal of Cancer*. 37(6): 169.

Sullivan, P., Bekir, S., Jaffar, Z., Page, C., Jeffery, P., Costello, J. (1994). Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. *Lancet*. 343: 1006-1008.

Suo, X.B., Zhang, H., Wang, Y.Q. (2007). HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. *Biomedical Chromatography*. 21: 730-734.

Szeffler, S.J., Wenzel, S., Brown, R., Erzurum, S.C., Fahy, J.V., Hamilton, R.G., Hunt, J.F., Kita, H., Liu, A.H., Panettieri, R.A. Jr, Schleimer, R.P., Minnicozzi, M. (2012). Asthma outcomes: biomarkers. *Journal of Allergy and Clinical Immunology*. 129(3): S9-23.

Takatsu, K., Nakajima, H. (2008). IL-5 and eosinophilia. *Current Opinion in Immunology*. 20(3): 288-294.

Talbot, S.F., Atkins, P.C., Goetzl, E.J., Zweiman, B. (1985). Accumulation of leukotriene C4 and histamine in human allergic skin reactions. *Journal of Clinical Investigation*. 76(2): 650-656.

Tan, M.L., Kuroyanagi, M., Sulaiman, S.F., Najimudin, N., Muhammad, T.S.T. (2005). Cytotoxic activities of major diterpenoid constituents of *Andrographis paniculata* in a panel of human tumor cell lines. *Pharmaceutical Biology*. 43: 501-508.

Tan, R.A., Corren, J. (2011). Safety of omalizumab in asthma. *Expert Opinion on Drug Safety*. 10(3):463-71.

Tanaka, T., Kobayashi, T., Sunaga, K., Tani, S. (2001). Effect of glucocorticoid on expression of rat MUC5AC mRNA in rat gastric mucosa in vivo and in vitro. *Biological and Pharmaceutical Bulletin*. 24(6): 634-637.

Tang, S.C. (2009). *Antiangiogenic and Antivasular Activities of Natural and Synthetic Compounds*. Unpublished master dissertation, Universiti Putra Malaysia, Malaysia.

Tanuma, N., Miyata, R., Hayashi, M., Uchiyama, A., Kurata, K. (2008). Oxidative stress as a biomarker of respiratory disturbance in patients with severe motor and intellectual disabilities. *Brain and Development*. 30(6): 402-409.

Taylor, A., Verhagen, J., Blaser, K., Akdis, M., Akdis, C.A. (2006). Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. *Immunology*. 117(4): 433-442.

Taylor, D.R. (2012). Advances in the clinical applications of exhaled nitric oxide measurements. *Journal of Breath Research*. 6(4): 047102.

Teo, S., Stirling, D., Thomas, S., Hoberman, A., Kiorpes, A., Khetani, V. (2002). A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. *Toxicology*. 179(3): 183-196.

Thisoda, P., Rangkadilok, N., Pholphana, N., Worasuttayangkurn, L., Ruchirawat, S., Satayavivad, J. (2006). Inhibitory effect of *Andrographis paniculata* extract and its active diterpenoids on platelet aggregation. *European Journal of Pharmacology*. 553(1-3): 39-45.



Thomas, P.S., Geddes, D.M., Barnes, P.J. (1999). Pseudo-steroid resistant asthma. *Thorax*. 54(4): 352-356.

Thomas, W.R., Hales, B.J. (2007). T and B cell responses to HDM allergens and antigens. *Immunologic Research*. 37(3): 187-199.

Thomson, N.C., Chaudhuri, R. (2012). Omalizumab: clinical use for the management of asthma. *Clinical Medicine Insights: Circulation, Respiratory and Pulmonary Medicine*. 6: 27-40.

Tofovic, S.P., Jackson, E.K. (1999). Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. *Journal of Cardiovascular Pharmacology*. 33(3): 360-366.

Tonnel, A.B., Joseph, M., Gosset, P., Fournier, E., Capron, A. (1983). Stimulation of alveolar macrophages in asthmatic patients after local provocation test. *Lancet*. 1: 1406-1408.

Trifilieff, A., Fujitani, Y., Mentz, F., Dugas, B., Fuentes, M., Bertrand, C. (2000). Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression. *Journal of Immunology*. 165(3): 1526-1533.

Tripp, C.S., Mahoney, M., Needleman, P. (1985). Calcium ionophore enables soluble agonists to stimulate macrophage 5-lipoxygenase. *Journal of Biological Chemistry*. 260(10): 5895-5898.

Trivedi, N.P., Rawal, U.M., Patel, B.P. (2007). Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. *Integrative Cancer Therapies*. 6(3): 271-280.

Tsai, H.R., Yang, L.M., Tsai, W.J., Chiou, W.F. (2004). Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. *European Journal of Pharmacology*. 498(1-3): 45-52.

Tsang, F., Fred Wong, W.S. (2000). Inhibitors of tyrosine kinase signaling cascade attenuated antigen challenge of guinea-pig airways in vitro. *American Journal of Respiratory and Critical Care Medicine*. 162(1): 126-133.

Ukena, D., Harnest, U., Sakalauskas, R., Magyar, P., Vetter, N., Steffen, H., Leichtl, S., Rathgeb, F., Keller, A., Steinijs, V.W. (1997). Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. *European Respiratory Journal*. 10: 2754-2760.

Umland, S.P., Nahrebne, D.K., Razac, S., Beavis, A., Pennline, K.J., Egan, R.W., Billah, M.M. (1997). The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. *Journal of Allergy and Clinical Immunology*. 100(4): 511-519.



Usmani, O.S., Ito, K., Maneechotesuwan, K., Ito, M., Johnson, M., Barnes, P.J., Adcock, I.M. (2005). Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. *American Journal of Respiratory and Critical Care Medicine*. 172: 704-712.

Van der Velden, J., Barker, D., Barcham, G., Koumoundouros, E., Snibson, K. (2012). Increased vascular density is a persistent feature of airway remodeling in a sheep model of chronic asthma. *Experimental Lung Research*. 38(6): 307-315.

Van-Vyve, T., Chanez, P., Bernard, A., Bousquet, J., Godard, P., Lauwerijs, R., Sibille, Y. (1995). Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects. *Journal of Allergy and Clinical Immunology*. 95: 60-68.

Varga, E.M., Durham, S.R. (2002). Allergen injection immunotherapy. *Journal of Allergy and Clinical Immunology*. 16: 533-549.

Vargaftig, B.B., Singer, M. (2003). Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. *American Journal Respiratory Cell and Molecular Biology*. 28(4): 410-419.

Vieth, M., Siegel, M.G., Higgs, R.E., Watson, I.A., Robertson, D.H., Savin, K.A., Durst, G.A., Hipskind, P.A. (2004). Characteristic physical properties and structural fragments of marketed oral drug. *Journal of Medicinal Chemistry*. 47: 224-232.

Vroliing, A.B., Duinsbergen, D., Fokkens, W.J., van Drunen, C.M. (2007). Allergen induced gene expression of airway epithelial cells shows a possible role for TNF- $\alpha$ . *Allergy*. 62: 1310-1319.

Walker, C., Virchow, J.C. Jr. (1993). T-cells and endothelial cells in asthma. *Allergy*. 48(17):24-31.

Wang, Y.H., Liu, Y.J. (2008). The IL-17 cytokine family and their role in allergic inflammation. *Current Opinion in Immunology*. 20(6): 697-702.

Wang, Z., Qiu, J., Guo, T.B., Liu, A., Wang, Y., Li, Y., Zhang, J.Z. (2007). Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. *Journal of Immunology*. 179(9): 5958-5965.

Wanner, A., Salathe, M., O'Riordan, T.G. (1996). Mucociliary clearance in the airways. *American Journal of Respiratory and Critical Care Medicine*. 154: 1868-1902.

Watanabe, J., Kozaki, A. (1978). Relationship between partition coefficients and apparent volumes of distribution for basic drugs. *Chemical and Pharmaceutical Bulletin (Tokyo)*. 26(2): 665-667.

Webb, D.C., McKenzie, A.N., Foster, P.S. (2001). Expression of the Ym2 lectin-binding protein is dependent on interleukin (IL)-4 and IL-13 signal transduction: identification of a novel allergy-associated protein. *Journal of Biological Chemistry*. 276(45): 41969-41976.

Wenzel, S., Holgate, S.T. (2006). The mouse trap: It still yields few answers in asthma. *American Journal of Respiratory and Critical Care Medicine*. 174(11): 1173-1176.

West, M., Mhatre, M., Ceballos, A., Floyd, R.A., Grammas, P., Gabbita, S.P., Hamdheydari, L., Mai, T., Mou, S., Pye, Q.N., Stewart, C., West, S., Williamson, K.S., Zemlan, F., Hensley, K. (2004). The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. *Journal of Neurochemistry*. 91(1): 133-143.

Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., Donaldson, D.D. (1998). Interleukin-13: Central mediator of allergic asthma. *Science*. 282: 2258.

Wills-Karp, M. (2004). Interleukin-13 in asthma pathogenesis. *Immunological Review*. 202: 175-190.

Wilson, A.J., Gibson, P.G., Coughlan, J. (2000) Long acting bagonists versus theophylline for maintenance treatment of asthma. *Cochrane Database of Systematic Reviews*. 2000: CD001281.

Wilson, D.R., Torres, L.M., Durham, S.R. (2003). Sublingual immunotherapy for allergic rhinitis. *Cochrane Database of Systematic Reviews*. 2003(2): CD002893.

Whittaker, L., Niu, N., Temann, U.A., Stoddard, A., Flavell, R.A., Ray, A., Homer, R.J., Cohn, L. (2002). Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. *American Journal of Respiratory and Cell Molecular Biology*. 27(5): 593-602.

WHO. (2002). WHO monographs on selected medicinal plants. World Health Organization. *Geneva*. 2: 12-25.

Wolyniec, W.W., De Sanctis, G.T., Nabozny, G., Torcellini, C., Haynes, N., Joetham, A., Gelfand, E.W., Drazen, J.M., Noonan, T.C. (1998). Reduction of antigen-induced airway hyperreactivity and eosinophilia in ICAM-1-deficient mice. *American Journal of Respiratory and Cell Molecular Biology*. 18(6): 777-785.

Wong, C.K., Ho, C.Y., Ko, F.W., Chan, C.H., Ho, A.S., Hui, D.S., Lam, C.W. (2001). Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. *Clinical and Experimental Immunology*. 125(2): 177-183.

Wong, H.C. (2012). *In Vitro Growth Inhibition, Molecular Mechanisms of Cell Cycle Arrest, and Apoptosis in Prostate Cancer Cells by Sizes*. Unpublished master dissertation, Universiti Putra Malaysia, Malaysia.

Wood, L.G., Gibson, P.G., Garg, M.L. (2003). Biomarkers of lipid peroxidation, airway inflammation and asthma. *European Respiratory Journal*. 21(1): 177-186.

Wood, L.G., Gibson, P.G. (2010). Reduced circulating antioxidant defences are associated with airway hyper-responsiveness, poor control and severe disease pattern in asthma. *British Journal of Nutrition*. 103(5): 735-741.

Wu, C.M., Cao, J.L., Zheng, M.H., Ou, Y., Zhang, L., Zhu, X.Q., Song, J.X. (2008). Effect and mechanism of andrographolide on the recovery of *Pseudomonas aeruginosa* susceptibility to several antibiotics. *Journal of International Medical Research*. 36(1): 178-86.

Xia, Y.F., Ye, B.Q., Li, Y.D., Wang, J.G., He, X.J., Lin, X., Yao, X., Ma, D., Slungaard, A., Hebbel, R.P., Key, N.S., Geng, J.G. (2004). Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. *Journal of Immunology*. 173(6): 4207-4217.

Xing, L., Remick, D.G. (2007). Promoter elements responsible for antioxidant regulation of MCP-1 gene expression. *Antioxidant and Redox Signaling*. 9(11):1979-1989.

Xiong, H., Zhu, C., Li, F., Hegazi, R., He, K., Babyatsky, M., Bauer, A.J., Plevy, S.E. (2004). Inhibition of interleukin-12 p40 transcription and NF-kappaB activation by nitric oxide in murine macrophages and dendritic cells. *Journal of Chemical Biology*. 279(11): 10776-10783.

Xu, H.W., Zhang, J., Liu, H.M., Wang, J.F. (2006). Synthesis of andrographolide cyclophosphate derivatives and their antitumor activities. *ChemInform*. 37: 407-414.

Xu, H.W., Dai, G.F., Liu, G.Z., Wang, J.F., Liu, H.M. (2007). Synthesis of andrographolide derivatives: A new family of alpha-glucosidase inhibitors. *Bioorganic & Medicinal Chemistry*. 15: 4247-4255.

Yakubu, M.T., Bilbis, L.S., Lawal, M., Akanji, M.A. (2003). Effect of repeated administration of sildenafil citrate on selected enzyme activities of liver and kidney of male albino rats. *Global Journal of Pure and Applied Sciences*. 18: 1395-1400.

Yamaguchi, T., Soma, T., Takaku, Y., Nakagome, K., Hagiwara, K., Kanazawa, M., Nagata, M. (2010). Salbutamol modulates the balance of Th1 and Th2 cytokines by mononuclear cells from allergic asthmatics. *International Archives of Allergy and Immunology*. 152(1): 32-40.

Yang, C.J., Liu, Y.K., Liu, C.L., Shen, C.N., Kuo, M.L., Su, C.C., Tseng, C.P., Yen, T.C., Shen, C.R. (2009). Inhibition of acidic mammalian chitinase by RNA interference suppresses ovalbumin-sensitized allergic asthma. *Human Gene Therapy*. 20(12): 1597-1606.

Yang, D., Zhang, W., Song, L., Guo, F. (2013). Andrographolide Protects against Cigarette Smoke-Induced Lung Inflammation through Activation of Heme Oxygenase-1. *Journal of Biochemical and Molecular Toxicology*. 27(5): 259-265.

Yang, L., Cohn, L., Zhang, D.H., Homer, R., Ray, A., Ray, P. (1998). Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. *Journal of Experimental Medicine*. 188(9): 1739-1750.

Yang, T., Xu, C., Wang, Z.T., Wang, C.H. (2013a). Comparative pharmacokinetic studies of andrographolide and its metabolite of 14-deoxy-12-hydroxy-andrographolide in rat by ultra-performance liquid chromatography-mass spectrometry. *Biomedical Chromatography*. 27(7): 931-937.

Yang, T., Sheng, H.H., Feng, N.P., Wei, H., Wang, Z.T., Wang, C.H. (2013b). Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity. *Journal of Pharmaceutical Science*. 102(12): 4414-4425.

Yick, C.Y., Ferreira, D.S., Annoni, R., von der Thüsen, J.H., Kunst, P.W., Bel, E.H., Lutter, R., Mauad, T., Sterk, P.J. (2012). Extracellular matrix in airway smooth muscle is associated with dynamics of airway function in asthma. *Allergy*. 67(4): 552-559.

Yim, R.P., Koumbourlis, A.C. (2012). Steroid-resistant asthma. *Paediatric Respiratory Reviews*. 13(3): 172-176.

Ying, L., Hofseth, L.J. (2007). An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. *Cancer Research*. 67: 1407-1410.

Yoopan, N., Thisoda, P., Rangkadilok, N., Sahasitawat, S., Pholphana, N., Ruchirawat, S., Satayavivad, J. (2007). Cardiovascular effects of 14-deoxy-11,12-didehydroandrographolide and *Andrographis paniculata* extracts. *Planta Medica*. 73(6): 503-511.

Yoshihara, S., Kanno, N., Yamada, Y., Ono, M., Fukuda, N., Numata, M., Abe, T., Arisaka, O. (2006). Effects of early intervention with inhaled sodium cromoglycate in childhood asthma. *Lung*. 184(2): 63-72.

Yu, B.T., Zhang, Z.R., Liu, W.S., Yang, T.P.W. (2002). Study on stability in vitro of andrographolide. *Traditional Chinese Patent Medicine*, 24(5): 33133.



Yu, B.C., Chang, C.K., Su, C.F., Cheng, J.T. (2008). Mediation of beta-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals. *Naunyn-Schmiedeberg's Archives of Pharmacology*. 377(4-6): 529-540.

Zainudin, B.M., Lai, C.K., Soriano, J.B., Jia-Horng, W., De Guia, T.S. (2005). Asthma Insights and Reality in Asia-Pacific (AIRIAP) Steering Committee. Asthma control in adults in Asia-Pacific. *Respirology*. 10(5): 579- 586.

Zamek-Gliszczynski, M.J., Hoffmaster, K.A., Nezasa, K., Tallman, M.N., Brouwer, K.L. (2006). Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. *European Journal of Pharmaceutical Sciences*. 27(5): 447-486.

Zangrilli, J.G., Shaver, J.R., Cirelli, R.A., Cho, S.K., Garlisi, C.G., Falcone, A., Cuss, F.M., Fish, J.E., Peters, S.P. (1995). VCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late-phase response. *American Journal of Respiratory and Critical Care Medicine*. 151: 1346-1353.

Zhao, J., Zhu, H., Wong, C.H., Leung, K.Y., Wong, W.S. (2005). Increased lungline and chitinase levels in allergic airway inflammation: a proteomics approach. *Proteomics*. 5(11):2799-2807.

Zhao, F., He, E.Q., Wang, L., Liu, K. (2008). Anti-tumor activities of andrographolide, a diterpene from *Andrographis paniculata*, by inducing apoptosis and inhibiting VEGF level. *Journal of Asian Natural Products Research*. 10(5-6): 467-473.

Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., Ghosh, S. (1997). The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. *Cell*. 89(3): 413-424.

Zhou, A., Scoggin, S., Gaynor, R.B., Williams, N.S. (2003). Identification of NF-kappa B-regulated genes induced by TNF alpha utilizing expression profiling and RNA interference. *Oncogene*. 22(13): 2054-2064.

Zhu, Z., Zheng, T., Homer, R.J., Kim, Y.K., Chen, N.Y., Cohn, L., Hamid, Q., Elias, J.A. (2004). Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. *Science*. 304(5677): 1678-1682.

Zhu, T., Wang, D.X., Zhang, W., Liao, X.Q., Guan, X., Bo, H., Sun, J.Y., Huang, N.W., He, J., Zhang, Y.K., Tong, J., Li, C.Y. (2013). Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-κB. *PLoS One*. 8(2): e56407.

Ziegelbauer, K., Gantner, F., Lukacs, N.W., Berlin, A., Fuchikami, K., Niki, T., Sakai, K., Inbe, H., Takeshita, K., Ishimori, M., Komura, H., Murata, T., Lowinger, T., Bacon, K.B. (2005). A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. *British Journal of Pharmacology*. 145(2): 178-192.



Zimmermann, N., King, N.E., Laporte, J., Yang, M., Mishra, A., Pope, S.M., Muntel, E.E., Witte, D.P., Pegg, A.A., Foster, P.S., Hamid, Q., Rothenberg, M.E. (2003). Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. *Journal of Clinical Investigation*. 111(12): 1863-1874.

Zingarelli, B., Sheehan, M., Wong, H.R. (2003). Nuclear factor-kappaB as a therapeutic target in critical care medicine. *Critical Care Medicine*. 31(1): S105-111.

Zosky, G.R., Sly, P.D. (2007). Animal models of asthma. *Clinical and Experimental Allergy*. 37(7): 973-988.

